Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-25T07:31:28.325Z Has data issue: false hasContentIssue false

The role of PfEMP1 as targets of naturally acquired immunity to childhood malaria: prospects for a vaccine

Published online by Cambridge University Press:  08 January 2016

PETER C. BULL*
Affiliation:
Department of Pathology, University of Cambridge, Tennis Court Rd, Cambridge CB2 1QP, UK Nuffield Department of Medicine Research Building, Centre for Tropical Medicine and Global Health, University of Oxford, Old Road Campus, Roosevelt Drive, Headington, Oxford OX3 7FZ, UK
ABDIRAHMAN I. ABDI
Affiliation:
Department of Pathology, University of Cambridge, Tennis Court Rd, Cambridge CB2 1QP, UK Department of Biochemistry and Chemistry, Pwani University, P.O. Box 195, 80108 Kilifi, Kenya
*
*Corresponding author: Peter Bull, Department of Pathology, University of Cambridge, Tennis Court Rd, Cambridge CB2 1QP, UK. E-mail: pb642@cam.ac.uk

Summary

The Plasmodium falciparum erythrocyte membrane protein 1 antigens that are inserted onto the surface of P. falciparum infected erythrocytes play a key role both in the pathology of severe malaria and as targets of naturally acquired immunity. They might be considered unlikely vaccine targets because they are extremely diverse. However, several lines of evidence suggest that underneath this molecular diversity there are a restricted set of epitopes which may act as effective targets for a vaccine against severe malaria. Here we review some of the recent developments in this area of research, focusing on work that has assessed the potential of these molecules as possible vaccine targets.

Type
Special Issue Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Cambridge University Press 2016

INTRODUCTION

When Plasmodium falciparum infect human erythrocytes, they insert into the erythrocyte surface parasite antigens that profoundly alter the antigenic properties of the cells (Langreth and Reese, Reference Langreth and Reese1979). These antigens play a central role in the pathology of severe malaria by mediating the cytoadhesion to various molecules on host cells (Rowe et al. Reference Rowe, Claessens, Corrigan and Arman2009) and sequestration of parasites in tissues including the brain, long known as a hallmark of fatal falciparum malaria in humans (Marchiafava and Bignami, Reference Marchiafava, Bignami and Marchiafava1894). One of their key features is that they undergo antigenic variation (Roberts et al. Reference Roberts, Craig, Berendt, Pinches, Nash, Marsh and Newbold1992) and for this reason they are collectively called variant surface antigens (VSA).

The feasibility of developing a malaria vaccine is supported by the observation that children growing up in malaria endemic areas develop naturally acquired immunity to malaria after several years of exposure (Wilson et al. Reference Wilson, Garnham and Swellengrebel1950). This immunity protects children from severe life threatening malaria and promotes the establishment of chronic, asymptomatic infections, to which even individuals growing up in malaria endemic areas remain susceptible for life (Marsh, Reference Marsh1992). In this review, we will focus on the role of the P. falciparum membrane protein 1 (PfEMP1) family of VSA as targets of naturally acquired immunity and review their potential as vaccine targets. There have been extremely encouraging developments in this area of research over the last 3 years. However, as our knowledge grows, so does our appreciation of the complexity of the parasite's strategy of evading our immune systems. There are no shortage of recent reviews that together give a comprehensive summary of variants surface antigens both in immunity and cytoadhesion (Rowe et al. Reference Rowe, Claessens, Corrigan and Arman2009; Chan et al. Reference Chan, Fowkes and Beeson2014; Smith, Reference Smith2014). Here, we will give an overview of what we think are the current key questions and gaps in our knowledge.

VSA are important targets of naturally acquired immunity

An early demonstration of the importance of VSA as immune targets was a serological study showing that, among seven different anti-blood stage assays including one measuring opsonization of infected erythrocytes, the titre in children's serum of antibodies that agglutinated infected erythrocytes from a single donor, was the only assay associated with reduced future experience of clinical malaria (Marsh et al. Reference Marsh, Otoo, Hayes, Carson and Greenwood1989). This apparent protection by anti-VSA antibodies against future disease is supported by more recent longitudinal studies by Dodoo et al. (Reference Dodoo, Staalsoe, Giha, Kurtzhals, Akanmori, Koram, Dunyo, Nkrumah, Hviid and Theander2001), where antibodies to infected erythrocytes of 2/5 parasite isolates showed a clear association with protection after age correction. Measures of antibodies to the infected erythrocyte surface present at the time of infection also show a negative association with the severity of disease, supporting a role in immunity (Tebo et al. Reference Tebo, Kremsner, Piper and Luty2002; Yone et al. Reference Yone, Kremsner and Luty2005). Consistent with this, chronic asymptomatic infections are associated with particularly high levels of antibodies to VSA and individuals who carry asymptomatic infections but do not make such responses tend to be more susceptible to future clinical malaria (Bull et al. Reference Bull, Lowe, Kaleli, Njuga, Kortok, Ross, Ndungu, Snow and Marsh2002; Kinyanjui et al. Reference Kinyanjui, Mwangi, Bull, Newbold and Marsh2004; Mackintosh et al. Reference Mackintosh, Mwangi, Kinyanjui, Mosobo, Pinches, Williams, Newbold and Marsh2008). The third approach used in early epidemiological studies was to test for carriage of antibodies that reverse cytoadhesion. The rosetting phenotype, defined as the binding of infected erythrocytes to uninfected erythrocytes, provides a good example. Carlson et al. (Reference Carlson, Helmby, Hill, Brewster, Greenwood and Wahlgren1990) found an association between the presence in children's serum of antibodies that reverse rosetting of a laboratory-adapted parasite line and (1) reduced rosetting in the children's own parasites and (2) absence of cerebral malaria. Antigen variants expressed on the surface of parasites from children with malaria was later shown to correspond with gaps in the repertoire of antibodies carried by the infected individual before they became ill (Bull et al. Reference Bull, Lowe, Kortok, Molyneux, Newbold and Marsh1998; Giha et al. Reference Giha, Staalsoe, Dodoo, Roper, Satti, Arnot, Hviid and Theander2000). Together, these data support a model of naturally acquired immunity to malaria through the gradual acquisition of many variant specific antibodies to VSA.

Such a model is consistent with the known dynamics of P. falciparum infections through information gathered during the time when malaria was used in the therapy of neurosyphilis (Whitrow, Reference Whitrow1990; Karamanou et al. Reference Karamanou, Liappas, Antoniou, Androutsos and Lykouras2013). The importance of VSA as targets of naturally acquired immunity to malaria is highlighted by the observation of clear recrudescence in parasitaemia followed by rapid decline. When these recrudescence occured, they did so with relatively consistent initial growth rates suggesting that new variants were emerging and were subsequently controlled on an otherwise only gradually changing immunological background (Molineaux et al. Reference Molineaux, Diebner, Eichner, Collins, Jeffery and Dietz2001).

Plasmodium falciparum encodes several multi-gene families including var, rif and stevor for which there is evidence of expression on the surface of parasite-infected erythrocytes (Baruch et al. Reference Baruch, Pasloske, Singh, Bi, Ma, Feldman, Taraschi and Howard1995; Smith et al. Reference Smith, Chitnis, Craig, Roberts, Hudson-Taylor, Peterson, Pinches, Newbold and Miller1995; Su et al. Reference Su, Heatwole, Wertheimer, Guinet, Herrfeldt, Peterson, Ravetch and Wellems1995; Cheng et al. Reference Cheng, Cloonan, Fischer, Thompson, Waine, Lanzer and Saul1998; Fernandez et al. Reference Fernandez, Hommel, Chen, Hagblom and Wahlgren1999; Kyes et al. Reference Kyes, Rowe, Kriek and Newbold1999; Niang et al. Reference Niang, Bei, Madnani, Pelly, Dankwa, Kanjee, Gunalan, Amaladoss, Yeo, Bob, Malleret, Duraisingh and Preiser2014; Goel et al. Reference Goel, Palmkvist, Moll, Joannin, Lara, Akhouri, Moradi, Ojemalm, Westman, Angeletti, Kjellin, Lehtio, Blixt, Idestrom, Gahmberg, Storry, Hult, Olsson, von Heijne, Nilsson and Wahlgren2015). Rif and stevor together with the majority of the 60 genes that make up the var gene family are located in the highly diverse sub-telomeric regions of chromosomes (Gardner et al. Reference Gardner, Hall, Fung, White, Berriman, Hyman, Carlton, Pain, Nelson, Bowman, Paulsen, James, Eisen, Rutherford, Salzberg, Craig, Kyes, Chan, Nene, Shallom, Suh, Peterson, Angiuoli, Pertea, Allen, Selengut, Haft, Mather, Vaidya and Martin2002). Of these families the var genes and the PfEMP1 antigens they encode have been the subject of the most research to date because of the role that PfEMP1 play both in cytoadhesion to many specific host receptors and the evidence for their role as targets of naturally acquired antibodies that undergo clonal antigenic variation.

An early study demonstrated how changes in PfEMP1 expression by a laboratory parasite line correlated with switches in both the antigenic and cytoadhesive properties of the infected erythrocyte surface (Biggs et al. Reference Biggs, Gooze, Wycherley, Wollish, Southwell, Leech and Brown1991). After the var genes had been identified (Baruch et al. Reference Baruch, Pasloske, Singh, Bi, Ma, Feldman, Taraschi and Howard1995; Smith et al. Reference Smith, Chitnis, Craig, Roberts, Hudson-Taylor, Peterson, Pinches, Newbold and Miller1995; Su et al. Reference Su, Heatwole, Wertheimer, Guinet, Herrfeldt, Peterson, Ravetch and Wellems1995), switches in var gene expression were correlated with both antigenic variation and altered ability of the parasites to bind to the host receptor molecule ICAM1 (Smith et al. Reference Smith, Chitnis, Craig, Roberts, Hudson-Taylor, Peterson, Pinches, Newbold and Miller1995). Many known host-cell-binding phenotypes identified in P. falciparum-infected erythrocytes have since been mapped onto regions of PfEMP1, including ICAM1 (Smith et al. Reference Smith, Craig, Kriek, Hudson-Taylor, Kyes, Fagan, Pinches, Baruch, Newbold and Miller2000; Bengtsson et al. Reference Bengtsson, Joergensen, Rask, Olsen, Andersen, Turner, Theander, Hviid, Higgins, Craig, Brown and Jensen2013), CD36 (Baruch et al. Reference Baruch, Ma, Singh, Bi, Pasloske and Howard1997; Smith et al. Reference Smith, Kyes, Craig, Fagan, Hudson-Taylor, Miller, Baruch and Newbold1998; Robinson et al. Reference Robinson, Welch and Smith2003), complement receptor 1(Rowe et al. Reference Rowe, Moulds, Newbold and Miller1997), heparin, blood group A antigen (Vigan-Womas et al. Reference Vigan-Womas, Guillotte, Juillerat, Hessel, Raynal, England, Cohen, Bertrand, Peyrard, Bentley, Lewit-Bentley and Mercereau-Puijalon2012) , Chondroitin sulphate A (Salanti et al. Reference Salanti, Staalsoe, Lavstsen, Jensen, Sowa, Arnot, Hviid and Theander2003), PECAM1 (Berger et al. Reference Berger, Turner, Wang, Petersen, Kraft, Lusingu, Mmbando, Marquard, Bengtsson, Hviid, Nielsen, Theander and Lavstsen2013), IgM (Ghumra et al. Reference Ghumra, Semblat, McIntosh, Raza, Rasmussen, Braathen, Johansen, Sandlie, Mongini, Rowe and Pleass2008) and endothelial protein C receptor (EPCR) (Turner et al. Reference Turner, Lavstsen, Berger, Wang, Petersen, Avril, Brazier, Freeth, Jespersen, Nielsen, Magistrado, Lusingu, Smith, Higgins and Theander2013). Recently, knockdowns of var gene expression in two laboratory lines resulted in almost complete loss of antibody recognition and cytoadhesive properties (Chan et al. Reference Chan, Howell, Reiling, Ataide, Mackintosh, Fowkes, Petter, Chesson, Langer, Warimwe, Duffy, Rogerson, Bull, Cowman, Marsh and Beeson2012), suggesting that PfEMP1 are the dominant antigens expressed on the surface of these laboratory-adapted parasite lines that are recognized by naturally acquired antibodies against infected erythrocytes.

Why is the feasibility of a PfEMP1 vaccine worth exploring?

PfEMP1 clearly plays an important role in the host–parasite interaction. However, PfEMP1 is, on the face of it, perhaps the last group of proteins that you might want to study as a malaria vaccine candidate. Early serological studies show that after an episode of disease, children develop antibodies that are highly specific to the parasites that caused that disease episode, suggesting that, at least the immune-dominant epitopes expressed on the infected erythrocyte surface are extremely diverse (Marsh and Howard, Reference Marsh and Howard1986; Forsyth et al. Reference Forsyth, Philip, Smith, Kum, Southwell and Brown1989; Iqbal et al. Reference Iqbal, Perlmann and Berzins1993; Reeder et al. Reference Reeder, Rogerson, Al-Yaman, Anders, Coppel, Novakovic, Alpers and Brown1994; Bull et al. Reference Bull, Lowe, Kortok and Marsh1999). Though they are encoded by a family of only 60 var genes in every genome, each genome is potentially a drop in the ocean of var diversity within the global parasite population and the potential for immune evasion through influx of new PfEMP1 variants through gene conversion would seem from these data to be immense. Barry et al. (Reference Barry, Leliwa-Sytek, Tavul, Imrie, Migot-Nabias, Brown, McVean and Day2007), sampled short tags of sequence from PfEMP1 from a worldwide collection of parasites and failed to find a limit to this sequence diversity. As new sequences were sampled randomly from the ‘pot’ of collected sequences, a point was never reached at which the rate of sampling of new sequences diminished (Barry et al. Reference Barry, Leliwa-Sytek, Tavul, Imrie, Migot-Nabias, Brown, McVean and Day2007). Recent evidence further suggests that var undergo mitotic recombination, potentially unpacking unlimited diversity from a single genome (Claessens et al. Reference Claessens, Hamilton, Kekre, Otto, Faizullabhoy, Rayner and Kwiatkowski2014).

Despite this immense molecular diversity children as they grow up in malaria endemic areas do learn to recognize antigens expressed on the surface of infected erythrocytes (Barragan et al. Reference Barragan, Kremsner, Weiss, Wahlgren and Carlson1998; Bull et al. Reference Bull, Lowe, Kortok, Molyneux, Newbold and Marsh1998) and cross-reactivity exists between epitopes expressed on the surface of infected erythrocytes sampled from different geographical areas and even different continents (Aguiar et al. Reference Aguiar, Albrecht, Cegielski, Greenwood, Jensen, Lallinger, Martinez, McGregor, Minjas, Neequaye, Patarroyo, Sherwood and Howard1992; Nielsen et al. Reference Nielsen, Vestergaard, Lusingu, Kurtzhals, Giha, Grevstad, Goka, Lemnge, Jensen, Akanmori, Theander, Staalsoe and Hviid2004). So why does antigenic variation in P. falciparum not always lead to infections that overwhelm the host? The life cycle of P. falciparum relies on the establishment of chronic blood stage infections and host survival through the dry season when pools of water necessary for mosquito reproduction are scarce and opportunities to transmit to mosquitos is low. The question of how the correct balance is maintained between too little and too much antigenic diversity; host survival and parasite escape from antibodies, is still one of the major questions in malaria parasite biology (Saul, Reference Saul1999). The generally accepted broad explanation is that antigenic diversity in PfEMP1 is constrained by its function in cytoadhering to host cells and bringing about sequestration of infected erythrocytes in tissue capillary beds and that inefficient cytoadhesion leads to passage of the infected erythrocytes through the spleen where they are removed from circulation (Barnwell et al. Reference Barnwell, Howard, Coon and Miller1983).

The idea that the functional role of PfEMP1 constrains its antigenic diversity forms an important part of the rationale for considering PfEMP1 as a viable vaccine target against severe malaria (see Fig. 1). This rationale stems from the way in which naturally acquired immunity develops. Children who grow up in malaria endemic areas probably never develop sterile immunity to P. falciparum. Immunity to severe malaria develops more rapidly than immunity to mild malaria as the host–parasite relationship changes from one associated with severe malaria and transmission to mosquitoes towards one that sustains chronic asymptomatic infections (Langhorne et al. Reference Langhorne, Ndungu, Sponaas and Marsh2008; Goncalves et al. Reference Goncalves, Huang, Morrison, Holte, Kabyemela, Prevots, Fried and Duffy2014; Griffin et al. Reference Griffin, Hollingsworth, Reyburn, Drakeley, Riley and Ghani2015). If constraints on PfEMP1 structure are imposed by effective cytoadhesion and avoidance of the host spleen, this could result in trade-off between antigenic novelty on the one hand and highly effective cytoadhesion on the other (Bull et al. Reference Bull, Lowe, Kortok and Marsh1999; Nielsen et al. Reference Nielsen, Staalsoe, Kurtzhals, Goka, Dodoo, Alifrangis, Theander, Akanmori and Hviid2002; Jensen et al. Reference Jensen, Magistrado, Sharp, Joergensen, Lavstsen, Chiucchiuini, Salanti, Vestergaard, Lusingu, Hermsen, Sauerwein, Christensen, Nielsen, Hviid, Sutherland, Staalsoe and Theander2004; Frank and Bush, Reference Frank and Bush2007; van Noort et al. Reference van Noort, Nunes, Weedall, Hviid and Gomes2010; Buckee and Recker, Reference Buckee and Recker2012; Severins et al. Reference Severins, Klinkenberg and Heesterbeek2012). If only strongly cytoadhesive PfEMP1 can mediate the level of sequestration that can bring about severe malaria and these variants are more structurally constrained and antigenically conserved, then it is possible to imagine this trade-off setting up a spectrum of variants differentially adapted to efficient cytoadhesion on the one hand and antibody evasion on the other. The observed shift in host–parasite interaction observed in children growing up exposed to malaria parasites could be brought about through rapid acquisition of immunity to the few types that support high levels of cytoadhesion and differential survival of parasites expressing variants that can only support uncomplicated and asymptomatic infections.

Fig. 1. Hypothetical trade-offs between function and antigenic novelty. This figure shows an immunological version of the principle of functional constraint focusing on efficiency of biological functions associated with the host–parasite interaction (y-axis) and the hypothetical antigenic space within which those functions exist (x-axis). Optimal function can only be performed by a narrow range of molecular structures which translates, in the simplest case, to a small antigenic space. Key to virulence is not simply the function itself, but the ability of molecules or systems of molecules to uncouple immunogenicity from function to expand the antigenic space available. Hypothetical lines are drawn to suggest trade-offs between function and antigenic space in for: (i) Measles haemagglutinin (Frank and Bush, Reference Frank and Bush2007), (ii) var2CSA, (iii) group A and DC8 PfEMP1 (Buckee and Recker, Reference Buckee and Recker2012), (iv) group B and C PfEMP1, (vi) HIV gp120 (de Boer and Boerlijst, Reference de Boer and Boerlijst1994). Following from this hypothetical trade-off, parasites with high levels of recognition by antibodies commonly carried by children have been proposed to express PfEMP1 variants with strong cytoadhesive function and exist within a small restricted immunological space. Such hypothetical variants have been called: agglutination frequency high (AFH (Bull et al. Reference Bull, Kortok, Kai, Ndungu, Ross, Lowe, Newbold and Marsh2000) VSA with a high frequency of recognition [VSAFoRH (Bull et al. Reference Bull, Pain, Ndungu, Kinyanjui, Roberts, Newbold and Marsh2005b)], and VSA associated with severe malaria [VSASM (Nielsen et al. Reference Nielsen, Staalsoe, Kurtzhals, Goka, Dodoo, Alifrangis, Theander, Akanmori and Hviid2002; Jensen et al. Reference Jensen, Magistrado, Sharp, Joergensen, Lavstsen, Chiucchiuini, Salanti, Vestergaard, Lusingu, Hermsen, Sauerwein, Christensen, Nielsen, Hviid, Sutherland, Staalsoe and Theander2004)]. Their position within the graph is indicated with a box

Evidence for this model comes first from the association between various cytoadhesion phenotypes and the severity of malaria (Carlson et al. Reference Carlson, Helmby, Hill, Brewster, Greenwood and Wahlgren1990; Rowe et al. Reference Rowe, Obeiro, Newbold and Marsh1995; Newbold et al. Reference Newbold, Warn, Black, Berendt, Craig, Snow, Msobo, Peshu and Marsh1997; Heddini et al. Reference Heddini, Pettersson, Kai, Shafi, Obiero, Chen, Barragan, Wahlgren and Marsh2001; Ochola et al. Reference Ochola, Siddondo, Ocholla, Nkya, Kimani, Williams, Makale, Liljander, Urban, Bull, Szestak, Marsh and Craig2011; Turner et al. Reference Turner, Lavstsen, Berger, Wang, Petersen, Avril, Brazier, Freeth, Jespersen, Nielsen, Magistrado, Lusingu, Smith, Higgins and Theander2013). The second line of evidence comes from studies that have examined variation in the serological commonness of antigens expressed on the surface of infected erythrocytes measured by panels of plasma or serum. Parasites from children with severe malaria and those who were very young tend to be more commonly recognized (Bull et al. Reference Bull, Lowe, Kortok and Marsh1999, Reference Bull, Kortok, Kai, Ndungu, Ross, Lowe, Newbold and Marsh2000; Nielsen et al. Reference Nielsen, Staalsoe, Kurtzhals, Goka, Dodoo, Alifrangis, Theander, Akanmori and Hviid2002). The fact that severe malaria is a rare manifestation of infection seems at odds with the idea that it is associated with commonly occurring variants and raises the question of why some children get severe malaria and others don't. We might hypothesize that the expression of subsets of commonly circulating PfEMP1 is necessary, if not sufficient, for the development of severe malaria. However, this would be at odds with the observation that parasites from 13/42 children with severe malaria in (Bull et al. Reference Bull, Kortok, Kai, Ndungu, Ross, Lowe, Newbold and Marsh2000) were not agglutinated by any of a panel of 15 children's plasma (Bull et al. Reference Bull, Pain, Ndungu, Kinyanjui, Roberts, Newbold and Marsh2005b). The serological profiles of commonly recognized parasites were also diverse showing that there may be many commonly recognized types circulating in the parasite population (Bull et al. Reference Bull, Lowe, Kortok and Marsh1999, Reference Bull, Kortok, Kai, Ndungu, Ross, Lowe, Newbold and Marsh2000, Reference Bull, Pain, Ndungu, Kinyanjui, Roberts, Newbold and Marsh2005b; Nielsen et al. Reference Nielsen, Staalsoe, Kurtzhals, Goka, Dodoo, Alifrangis, Theander, Akanmori and Hviid2002).

PfEMP1 structure reflects the tension between cytoadhesive function and antigenic novelty

The structure of PfEMP1 nicely reflects its dual role as an antigenically variant cytoadhesive molecule. Despite considerable molecular diversity and length variation between the PfEMP1 variants, there is underlying structural conservation at various levels. This can be summarized as follows: (1) the molecules are constructed from only two broad classes of domain [see (Higgins and Carrington, Reference Higgins and Carrington2014) for a recent review]. The most common type of domain, ‘duffy binding-like’ (DBL) exists in several forms in Plasmodium species, in the duffy blood group binding protein in Plasmodium vivax, and in P. falciparum, the EBA140 and EBA175 erythrocyte-binding antigens and in the MSPDBL2 merozoite surface protein. The other domain type found in PfEMP1 is called the ‘cysteine-rich interdomain region’ (CIDR). (2) Both CIDR and DBL contain blocks of sequence (homology blocks) that are relatively conserved. These homology blocks can be used to divide each domain type into various classes and subclasses (Rask et al. Reference Rask, Hansen, Theander, Gorm Pedersen and Lavstsen2010). (3) The key feature of these domain subclasses is that they represent deep divisions within the sequences. These broad classes of domain are commonly encountered between different parasite isolates and antigenic differences found within each parasite genome appear to be broadly conserved (Joergensen et al. Reference Joergensen, Turner, Magistrado, Dahlback, Vestergaard, Lusingu, Lemnge, Salanti, Theander and Jensen2006, Reference Joergensen, Vestergaard, Turner, Magistrado, Lusingu, Lemnge, Theander and Jensen2007). This is reminiscent of the deep divide seen within MHC genes (Klein and O'Huigin, Reference Klein and O'Huigin1994) and is supported by the existence of a similar range of common sequence features in var sequences from Plasmodium reichenowi, a parasite species similar to P. falciparum that infects chimpanzees (Bull et al. Reference Bull, Buckee, Kyes, Kortok, Thathy, Guyah, Stoute, Newbold and Marsh2008; Zilversmit et al. Reference Zilversmit, Chase, Chen, Awadalla, Day and McVean2013; Otto et al. Reference Otto, Rayner, Bohme, Pain, Spottiswoode, Sanders, Quail, Ollomo, Renaud, Thomas, Prugnolle, Conway, Newbold and Berriman2014). In the case of PfEMP1 domains, specific cytoadhesive phenotypes are associated with specific domain subtypes (Fig. 2 and Table 1). (4) Finally, the predicted three-dimensional structures of these domains tends to be conserved and PfEMP1 molecules associated with childhood malaria are thought to exist as loose modular string of domains each with one of two basic structures (Klein et al. Reference Klein, Gittis, Su, Makobongo, Moore, Singh, Miller and Garboczi2008; Higgins and Carrington, Reference Higgins and Carrington2014).

Fig. 2. The structures of some notable PfEMP1 variants. Duffy-binding domains (DBL) are shown as rectangles and cysteine-rich interdomain regions (CIDR) and the CIDR-like domain of var2CSA are shown as ovals, N-terminal segment and acidic terminal segment (ATS) sequences are shown as hatched and stippled squares, respectively. ID2a and ID2b are interdomain regions within var2CSA that from part of the DBL2X CSA-binding domain (Clausen et al. Reference Clausen, Christoffersen, Dahlback, Langkilde, Jensen, Resende, Agerbaek, Andersen, Berisha, Ditlev, Pinto, Nielsen, Theander, Larsen and Salanti2012). Cytoadhesion phenotypes associated with specific domains are shown as colours. Recombinant proteins derived from these PfEMP1 are shown as black horizontal lines under the region of the molecules from which they were derived a, b, c, d, e, f. Domain cassettes are shown as horizontal dashed lines: a, the Id1-DBL2X region can stimulate antibodies in mice that inhibit CSA binding (Bordbar et al. Reference Bordbar, Tuikue-Ndam, Bigey, Doritchamou, Scherman and Deloron2012); b, The r179 region of CD36-binding CIDR from the Malayan Camp line used by Baruch et al. (Reference Baruch, Ma, Singh, Bi, Pasloske and Howard1997) to induce homologous protection in Aotus monkeys; c, the region of the IgM binding, rosette mediating TM284var1 used by Ghumra et al. (Reference Ghumra, Semblat, Ataide, Kifude, Adams, Claessens, Anong, Bull, Fennell and Arman2012) to induce cross-reactive, opsonizing antibodies in rabbits; IT4var60 was found to be the rosette mediating var in the well-studied cell line FCR3S1·2 (Albrecht et al. Reference Albrecht, Moll, Blomqvist, Normark, Chen and Wahlgren2011); d,e, constructs from non-IgM-binding, rosette-mediating PfEMP1 found to induce non-cross-reactive, rosette-inhibiting antibodies (Vigan-Womas et al. Reference Vigan-Womas, Guillotte, Juillerat, Vallieres, Lewit-Bentley, Tall, Baril, Bentley and Mercereau-Puijalon2011); (Ghumra et al. Reference Ghumra, Semblat, Ataide, Kifude, Adams, Claessens, Anong, Bull, Fennell and Arman2012); The R29 line was recently found to simultaneously form rosettes and bind to human brain endothelial cells (Adams et al. Reference Adams, Kuhnrae, Higgins, Ghumra and Rowe2014); f, naturally acquired antibodies to the DBLβ4 domain of pf11_0008 were associated with protection from future malaria in a longitudinal study (Magistrado et al. Reference Magistrado, Lusingu, Vestergaard, Lemnge, Lavstsen, Turner, Hviid, Jensen and Theander2007). A PECAM1-binding domain cassette (DC5) was subsequently identified within this gene (Berger et al. Reference Berger, Turner, Wang, Petersen, Kraft, Lusingu, Mmbando, Marquard, Bengtsson, Hviid, Nielsen, Theander and Lavstsen2013). Also shown are DCs, DC4 found to bind ICAM1 (Bengtsson et al. Reference Bengtsson, Joergensen, Rask, Olsen, Andersen, Turner, Theander, Hviid, Higgins, Craig, Brown and Jensen2013), identified within var4 previously found to be dominantly expressed in parasites selected for binding to antibodies from semi-immune children (Jensen et al. Reference Jensen, Magistrado, Sharp, Joergensen, Lavstsen, Chiucchiuini, Salanti, Vestergaard, Lusingu, Hermsen, Sauerwein, Christensen, Nielsen, Hviid, Sutherland, Staalsoe and Theander2004). Note the additional presence of a CIDRα1.6 within var4, shown to bind to EPCR by Lau et al. (Reference Lau, Turner, Jespersen, Lowe, Petersen, Wang, Petersen, Lusingu, Theander, Lavstsen and Higgins2015) but not by Turner et al. (Reference Turner, Lavstsen, Berger, Wang, Petersen, Avril, Brazier, Freeth, Jespersen, Nielsen, Magistrado, Lusingu, Smith, Higgins and Theander2013). IT4var6 and IT4var19 were two genes selected for binding to cells lines derived from human brain endothelial cells (Avril et al. Reference Avril, Tripathi, Brazier, Andisi, Janes, Soma, Sullivan, Bull, Stins and Smith2012; Claessens et al. Reference Claessens, Adams, Ghumra, Lindergard, Buchan, Andisi, Bull, Mok, Gupta and Wang2012), within which the DC8 and the EPCR-binding CIDRa1·1 domain was identified (Turner et al. Reference Turner, Lavstsen, Berger, Wang, Petersen, Avril, Brazier, Freeth, Jespersen, Nielsen, Magistrado, Lusingu, Smith, Higgins and Theander2013).

Table 1. Immunological studies on PfEMP1 domains

DC, domain cassette; SD, sub-domain; HB, homology block; var, commonly used model var; SM, association between expression and disease severity; C/R Ab, Whether cross-reactive antibodies have been detected; P. reich., identification of structure in Plasmodium reichenowi; antibodies, source of antibodies used; protection, the method used to demonstrate that antibodies are protective; longitudinal, longitudinal cohort studies of human populations; adhesion, reversal of infected erythrocyte adhesion; vaccination, protection demonstrated by vaccinating animals; anti-roset, rosette disruption by antibodies. RD, malaria with respiratory distress.

References: 1. Ghumra et al. (Reference Ghumra, Semblat, Ataide, Kifude, Adams, Claessens, Anong, Bull, Fennell and Arman2012); 2. Stevenson et al. (Reference Stevenson, Huda, Jeppesen, Laursen, Rowe, Craig, Streicher, Barfod and Hviid2014); 3. Berger et al. (Reference Berger, Turner, Wang, Petersen, Kraft, Lusingu, Mmbando, Marquard, Bengtsson, Hviid, Nielsen, Theander and Lavstsen2013); 4. Jensen et al. (Reference Jensen, Magistrado, Sharp, Joergensen, Lavstsen, Chiucchiuini, Salanti, Vestergaard, Lusingu, Hermsen, Sauerwein, Christensen, Nielsen, Hviid, Sutherland, Staalsoe and Theander2004); 5. Bengtsson et al. (Reference Bengtsson, Joergensen, Rask, Olsen, Andersen, Turner, Theander, Hviid, Higgins, Craig, Brown and Jensen2013); 6. Lau et al. (Reference Lau, Turner, Jespersen, Lowe, Petersen, Wang, Petersen, Lusingu, Theander, Lavstsen and Higgins2015); 7. Janes et al. (Reference Janes, Wang, Levin-Edens, Vigan-Womas, Guillotte, Melcher, Mercereau-Puijalon and Smith2011); 8. Avril et al. (Reference Avril, Tripathi, Brazier, Andisi, Janes, Soma, Sullivan, Bull, Stins and Smith2012); 9. Claessens et al. (Reference Claessens, Adams, Ghumra, Lindergard, Buchan, Andisi, Bull, Mok, Gupta and Wang2012); 10. Lavstsen et al. (Reference Lavstsen, Turner, Saguti, Magistrado, Rask, Jespersen, Wang, Berger, Baraka, Marquard, Seguin-Orlando, Willerslev, Gilbert, Lusingu and Theander2012); 11. Turner et al. (Reference Turner, Lavstsen, Berger, Wang, Petersen, Avril, Brazier, Freeth, Jespersen, Nielsen, Magistrado, Lusingu, Smith, Higgins and Theander2013); 12. Gamain et al. (Reference Gamain, Miller and Baruch2001); 13. Magistrado et al. (Reference Magistrado, Lusingu, Vestergaard, Lemnge, Lavstsen, Turner, Hviid, Jensen and Theander2007); 14. Vigan-Womas et al. (Reference Vigan-Womas, Guillotte, Juillerat, Vallieres, Lewit-Bentley, Tall, Baril, Bentley and Mercereau-Puijalon2011); 15. Vigan-Womas et al. (Reference Vigan-Womas, Guillotte, Juillerat, Hessel, Raynal, England, Cohen, Bertrand, Peyrard, Bentley, Lewit-Bentley and Mercereau-Puijalon2012); 16. Angeletti et al. (Reference Angeletti, Albrecht, Blomqvist, Quintana Mdel, Akhter, Bachle, Sawyer, Sandalova, Achour, Wahlgren and Moll2012); 17. Albrecht et al. (Reference Albrecht, Angeletti, Moll, Blomqvist, Valentini, D'Alexandri, Maurer and Wahlgren2014); 18. Normark et al. (Reference Normark, Nilsson, Ribacke, Winter, Moll, Wheelock, Bayarugaba, Kironde, Egwang, Chen, Andersson and Wahlgren2007); 19. Blomqvist et al. (Reference Blomqvist, Albrecht, Quintana Mdel, Angeletti, Joannin, Chene, Moll and Wahlgren2013); 20. Patarroyo et al. (Reference Patarroyo, Alba, Curtidor, Vanegas, Almonacid and Patarroyo2014).

Functional specialization is supported by serological and expression studies

A single clear example shows how effectively evolution has shaped the PfEMP1 repertoire to adapt both immunologically and functionally to its host. Malaria in pregnancy is associated with a single PfEMP1 variant encoded by var2CSA (Salanti et al. Reference Salanti, Staalsoe, Lavstsen, Jensen, Sowa, Arnot, Hviid and Theander2003, see Box 1). This PfEMP1 binds specifically to chondroitin sulphate A but not to CD36 and is adapted to bind to syncitiotrophoblasts in the placenta. Parasites isolated from placenta are poorly recognized by antibodies from children, male adults and women during their first pregnancy but immunity develops during subsequent pregnancies, explaining the observed parity dependency in susceptibility to placental malaria (Beeson et al. Reference Beeson, Brown, Molyneux, Mhango, Dzinjalamala and Rogerson1999).

Box 1. Lessons from VAR2CSA.

VAR2CSA presents us with what on the surface seemed like the best case scenario for developing a PfEMP1-based vaccine to targeting severe malaria. This has been more challenging perhaps than the expected but this should not be used as evidence that a vaccine based on other, more variable PfEMP1 involved in childhood malaria will be substantially more difficult to achieve.

The reason is that, unlike PfEMP1 associated with childhood malaria, VAR2CSA forms a compact structure, possibly due to the nature of the molecules to which it binds and the immunogenicity of the entire molecule is very different from the individual domains (Higgins and Carrington, Reference Higgins and Carrington2014). This difference with other PfEMP1 is consistent with the fact that var2CSA is not genetically connected to the network of gene conversion events that occur between other var genes. If all var genes had compact structures these would be disrupted each time the genes recombined with other var genes. A modular structure is likely to be more robust to their mode of variation through recombination.

One specific challenge in the case of VAR2CSA is that naturally acquired immune responses tends to target regions DBL3X and DBL5e that are masked by their ability to bind non-specifically to IgM (Barfod et al. Reference Barfod, Dalgaard, Pleman, Ofori, Pleass and Hviid2011). Though some PfEMP1 associated with childhood malaria bind non-specifically to IgM, there is no evidence that they play a role in masking antigenic sites (Stevenson et al. 2014). Despite the non-specific binding to IgM (Lambert et al. Reference Lambert, Bullock, Cook, Miura, Garboczi, Diakite, Fairhurst, Singh and Long2014) have shown that naturally acquired opsonizing antibodies to infected erythrocytes expressing var2CSA can be inhibited by incubation with DBL2X, DBL3X or DBL5ε domains. The N-terminal NTS-DBL2X region of the molecule is a prime target because antibodies raised to this region effectively block adhesion to CSA (Bigey et al. Reference Bigey, Gnidehou, Doritchamou, Quiviger, Viwami, Couturier, Salanti, Nielsen, Scherman, Deloron and Tuikue Ndam2011; Bordbar et al. 2012; Nunes-Silva et al. Reference Nunes-Silva, Gangnard, Vidal, Vuchelen, Dechavanne, Chan, Pardon, Steyaert, Ramboarina, Chene and Gamain2014). Doritchamou et al. (Reference Doritchamou, Bigey, Nielsen, Gnidehou, Ezinmegnon, Burgain, Massougbodji, Deloron, Salanti and Ndam2013) have suggested that bivalent vaccine based on this region might be sufficient to provide broad protection. However, the DBL2X region alone can stimulate antibodies in mice that inhibit CSA binding (Bordbar et al. Reference Bordbar, Tuikue-Ndam, Bigey, Doritchamou, Scherman and Deloron2012) and structural studies have confirmed the location of the CSA-binding region within this domain (Clausen et al. Reference Clausen, Christoffersen, Dahlback, Langkilde, Jensen, Resende, Agerbaek, Andersen, Berisha, Ditlev, Pinto, Nielsen, Theander, Larsen and Salanti2012).

There appear to be fitness differences in naturally occurring var2CSA. Specific var2CSA sequences appear to be associated with high parasitaemia infections. This may suggest evolution of sequences to evade host antibodies, or that some sequences bind more strongly to chondroitin sulphate A (Rovira-Vallbona et al. Reference Rovira-Vallbona, Monteiro, Bardaji, Serra-Casas, Neafsey, Quelhas, Valim, Alonso, Dobano, Ordi, Menendez and Mayor2013).

This functional specialization shapes the entire PfEMP1 repertoire. PfEMP1 associated with childhood malaria can be divided into three broad groups, A, B and C defined by upstream (ups) elements A, B and C, respectively (Lavstsen et al. Reference Lavstsen, Salanti, Jensen, Arnot and Theander2003). Unlike the majority of var genes, those in group C are located in clusters close to centromeres. Diversity of var genes is maintained by gene conversion events that occur between non-homologous positions within the genome. As a result the architectures of var genes, that is, the combinations and number of various DBL and CIDR domains, are highly variable between genomes (Kraemer and Smith, Reference Kraemer and Smith2003). Despite this, the group A genes appear to be relatively genetically isolated from the B and C genes. Group A PfEMP1 also tend to be longer and contain more DBL and CIDR domains. In contrast, there is evidence for considerable gene conversion between B and C var genes (Kraemer and Smith, Reference Kraemer and Smith2003; Kraemer et al. Reference Kraemer, Kyes, Aggarwal, Springer, Nelson, Christodoulou, Smith, Wang, Levin, Newbold, Myler and Smith2007; Rask et al. Reference Rask, Hansen, Theander, Gorm Pedersen and Lavstsen2010).

Expression of group A PfEMP1 by the infecting parasite population tends to be associated with infections of children with low immunity. This class of PfEMP1 tends to be recognized first as children are exposed to malaria parasites during the first few years of their lives. Parasites selected in vitro for recognition by pooled children's antibodies have a tendency to express Group A PfEMP1 (Jensen et al. Reference Jensen, Magistrado, Sharp, Joergensen, Lavstsen, Chiucchiuini, Salanti, Vestergaard, Lusingu, Hermsen, Sauerwein, Christensen, Nielsen, Hviid, Sutherland, Staalsoe and Theander2004). Recombinant domains from PfEMP1 are recognized in a hierarchical manner and group A PfEMP1 are the first to be recognized (Cham et al. Reference Cham, Turner, Lusingu, Vestergaard, Mmbando, Kurtis, Jensen, Salanti, Lavstsen and Theander2009, Reference Cham, Turner, Kurtis, Mutabingwa, Fried, Jensen, Lavstsen, Hviid, Duffy and Theander2010). Finally, parasite expression of group A-like PfEMP1 is differentially selected against in vivo as children develop antibodies against the IE surface (Bull et al. Reference Bull, Berriman, Kyes, Quail, Hall, Kortok, Marsh and Newbold2005a; Rottmann et al. Reference Rottmann, Lavstsen, Mugasa, Kaestli, Jensen, Muller, Theander and Beck2006; Warimwe et al. Reference Warimwe, Keane, Fegan, Musyoki, Newton, Pain, Berriman, Marsh and Bull2009, Reference Warimwe, Fegan, Musyoki, Newton, Opiyo, Githinji, Andisi, Menza, Kitsao, Marsh and Bull2012) (see Table 2). In contrast, the expression of group C var genes tends, at least in children from Papua New Guinea, to be differentially elevated in children with asymptomatic infections (Kaestli et al. Reference Kaestli, Cockburn, Cortes, Baea, Rowe and Beck2006; Falk et al. Reference Falk, Kaestli, Qi, Ott, Baea, Cortes and Beck2009).

Table 2. A summary of PfEMP1 expression studies in clinical parasite isolates

Positive and negative associations are shown as + and − symbol, respectively, lack of association is shown as 0, blank means that the comparison was not done. Four levels of immunity are described: Disease severity refers to comparisons between severe and mild malaria, Asymptomatic refers to comparisons between asymptomatic and symptomatic infection; age refers to whether there was an association with higher age of the parasite donor at the time of infection; antibodies asks whether there was an association between var expression and levels of antibodies to infected erythrocytes. Var expression is described as A, Group A; B, group B; C, group C; 8, DC8; 13, DC13; H, Homogenetiy of the var expression profile i.e. the extent to which a single variant dominates. Methods: DBLαtag, an expressed sequence tag approach using cloned and sequenced, PCR amplified tags from the DBLα domain; qPCR, quantitative PCR using domain specific primers; MS, Mass spectrometry; MA, microarray.

References for each study are coded as follows: 1. Kirchgatter and Portillo Hdel (Reference Kirchgatter and Portillo Hdel2002); 2. Kaestli et al. (Reference Kaestli, Cockburn, Cortes, Baea, Rowe and Beck2006); 3. Falk et al. (Reference Falk, Kaestli, Qi, Ott, Baea, Cortes and Beck2009); 4. Bull et al. (Reference Bull, Berriman, Kyes, Quail, Hall, Kortok, Marsh and Newbold2005a); 5. Warimwe et al. (Reference Warimwe, Keane, Fegan, Musyoki, Newton, Pain, Berriman, Marsh and Bull2009); 6. Warimwe et al. (Reference Warimwe, Fegan, Musyoki, Newton, Opiyo, Githinji, Andisi, Menza, Kitsao, Marsh and Bull2012); 7. Warimwe et al. (Reference Warimwe, Fegan, Musyoki, Newton, Opiyo, Githinji, Andisi, Menza, Kitsao, Marsh and Bull2013); 8. Rottmann et al. (Reference Rottmann, Lavstsen, Mugasa, Kaestli, Jensen, Muller, Theander and Beck2006); 9. Lavstsen et al. (Reference Lavstsen, Turner, Saguti, Magistrado, Rask, Jespersen, Wang, Berger, Baraka, Marquard, Seguin-Orlando, Willerslev, Gilbert, Lusingu and Theander2012); 10. Tembo et al. (Reference Tembo, Nyoni, Murikoli, Mukaka, Milner, Berriman, Rogerson, Taylor, Molyneux, Mandala, Craig and Montgomery2014); 11. Normark et al. (Reference Normark, Nilsson, Ribacke, Winter, Moll, Wheelock, Bayarugaba, Kironde, Egwang, Chen, Andersson and Wahlgren2007); 12. Kyriacou et al. (Reference Kyriacou, Stone, Challis, Raza, Lyke, Thera, Kone, Doumbo, Plowe and Rowe2006); 13. Kalmbach et al. (Reference Kalmbach, Rottmann, Kombila, Kremsner, Beck and Kun2010); 14. Merrick et al. (Reference Merrick, Huttenhower, Buckee, Amambua-Ngwa, Gomez-Escobar, Walther, Conway and Duraisingh2012); 15. Bertin et al. (Reference Bertin, Lavstsen, Guillonneau, Doritchamou, Wang, Jespersen, Ezimegnon, Fievet, Alao, Lalya, Massougbodji, Ndam, Theander and Deloron2013); 16. Almelli et al. (Reference Almelli, Nuel, Bischoff, Aubouy, Elati, Wang, Dillies, Coppee, Ayissi, Basco, Rogier, Ndam, Deloron and Tahar2014).

This antigenic separation between group A and non-group A PfEMP1 reflects a functional difference between these two broad classes. Recombinant CIDR domains from the ‘head structure’ (i.e. the first DBL and CIDR domain) of non-group A PfEMP1 molecules usually bind to CD36, while those from group A PfEMP1 do not (Robinson et al. Reference Robinson, Welch and Smith2003; Janes et al. Reference Janes, Wang, Levin-Edens, Vigan-Womas, Guillotte, Melcher, Mercereau-Puijalon and Smith2011). Recently, the phenomenon of mitotic recombination that would lead to immense additional PfEMP1 diversity appears to be restricted to non-group A PfEMP1 (Claessens et al. Reference Claessens, Hamilton, Kekre, Otto, Faizullabhoy, Rayner and Kwiatkowski2014). Together these observations are consistent with the idea of a trade-off between function and antigenic novelty shaping the genomic organization of the var gene family.

Exceptions to the molecular ‘rules’ may enable parasites to evade antibodies, prolong infections and cause severe malaria

For the sake of clarity, we have greatly simplified the distinction made above between the three classes of PfEMP1 types A, B and C. There are clear exceptions to these classifications and these exceptions to the norm may be of importance to our understanding of how these molecules evade antibodies. A transitional group between A and B PfEMP1 genes (B/A) exist that have upsB promotors but are otherwise like group A genes (Lavstsen et al. Reference Lavstsen, Salanti, Jensen, Arnot and Theander2003) and are predicted not to bind CD36 (Robinson et al. Reference Robinson, Welch and Smith2003). Similarly transitional genes between groups B & C (B/C) are common (Lavstsen et al. Reference Lavstsen, Salanti, Jensen, Arnot and Theander2003). The existence of transitional groups indicates that the three classes of genes, cannot be considered as genetically distinct families of molecules.

To refine our understanding of var gene organization, Rask et al. (Reference Rask, Hansen, Theander, Gorm Pedersen and Lavstsen2010) developed a system of classification that works from the level of individual homology blocks and domain subclasses to define common structures within var genes independent of their upstream promotors. This has greatly expanded our ability to describe similarity and differences between PfEMP1 molecules. The most immediately useful idea has been that of the ‘domain cassette’ (DC). The most prominent DCs are shown in Fig. 2 and Table 1. Two DCs in particular, DC8 and DC13 are of interest because genes containing these were found to be enriched by selecting infected erythrocytes for in vitro adhesion to cell lines derived from human brain endothelial cells (Avril et al. Reference Avril, Tripathi, Brazier, Andisi, Janes, Soma, Sullivan, Bull, Stins and Smith2012; Claessens et al. Reference Claessens, Adams, Ghumra, Lindergard, Buchan, Andisi, Bull, Mok, Gupta and Wang2012) and are expressed in children with severe malaria (Lavstsen et al. Reference Lavstsen, Turner, Saguti, Magistrado, Rask, Jespersen, Wang, Berger, Baraka, Marquard, Seguin-Orlando, Willerslev, Gilbert, Lusingu and Theander2012). Specific CIDR domain subclasses found within these DCs, instead of binding to CD36, are associated with binding to EPCR Adhesion to EPCR has been proposed to cause dysregulation of inflammation in the brain leading to cerebral malaria (Moxon et al. Reference Moxon, Wassmer, Milner, Chisala, Taylor, Seydel, Molyneux, Faragher, Esmon, Downey, Toh, Craig and Heyderman2013; Turner et al. Reference Turner, Lavstsen, Berger, Wang, Petersen, Avril, Brazier, Freeth, Jespersen, Nielsen, Magistrado, Lusingu, Smith, Higgins and Theander2013). CIDR domains important to EPCR binding contain conserved epitopes close to the EPCR-binding site that are recognized by malaria-exposed children (Lau et al. Reference Lau, Turner, Jespersen, Lowe, Petersen, Wang, Petersen, Lusingu, Theander, Lavstsen and Higgins2015). In terms of vaccine development, these results are encouraging and further support the idea of broad functional specialization within PfEMP1 family.

Overall these studies demonstrate that modularity exists at various levels within the structure of PfEMP1 associated with childhood malaria: at the level of DCs, domain classes and homology blocks. This would potentially enable different functional and antigenic components to exist in varying contexts. Whether this modularity could delay responses to previously encountered functional domains through re-assortment of T-cell and B-cell epitopes is yet to be explored. Buckee and Recker (Reference Buckee and Recker2012) have suggested that the existence of large numbers of different functional domains on group A PfEMP1 could enable these molecules to support endothelial binding even after antibodies have reversed binding mediated by one or more of the domains. The observation of highly homogeneous expression of group A PfEMP1 in the presence of high levels of antibodies in both severe malaria (Warimwe et al. Reference Warimwe, Recker, Kiragu, Buckee, Wambua, Musyoki, Marsh and Bull2013) and asymptomatic infection (Warimwe et al. Reference Warimwe, Fegan, Musyoki, Newton, Opiyo, Githinji, Andisi, Menza, Kitsao, Marsh and Bull2012) suggests that these antigenically more conserved variants can survive in individuals with high antibody responses, highlighting the need to fully understand how parasites evade antibodies. We have tended to emphasize the rapid acquisition of immunity to severe non-cerebral malaria (Gupta et al. Reference Gupta, Snow, Donnelly, Marsh and Newbold1999b) rather than the fact that cerebral malaria has a slightly later age prevalence than other forms of severe malaria (Greenwood et al. Reference Greenwood, Marsh and Snow1991; Marsh, Reference Marsh1992; Gupta et al. Reference Gupta, Snow, Donnelly and Newbold1999a; Roca-Feltrer et al. Reference Roca-Feltrer, Carneiro, Smith, Schellenberg, Greenwood and Schellenberg2010; Griffin et al. Reference Griffin, Hollingsworth, Reyburn, Drakeley, Riley and Ghani2015) and may involve the ability of parasites to effectively escape from the existing antibody responses (see also Box 2).

Box 2. The link between virulence and transmission.

Why are some PfEMP1 variants associated with more virulence than others? One suggestion from evolution of virulence theory, is that a trade-off exists between parasite virulence and effective transmission (Mackinnon and Read, Reference Mackinnon and Read2004), i.e. that some level of virulence is required for competitive transmission to new hosts. For this reason, Hayward et al. (Reference Hayward, Tiwari, Piper, Baruch and Day1999) attempted to demonstrate a close mechanistic link by demonstrating what appeared to be normal expression of CD36-binding PfEMP1 on early gametocytes. However, more recent data suggest that the link between the PfEMP1 expression and transmission is indirect since early gametocytes have a very different programme of PfEMP1 expression (Alano, Reference Alano2014; Ankarklev et al. Reference Ankarklev, Brancucci, Goldowitz, Mantel and Marti2014). Recent articles have re-emphasized the link between virulence and transmissibility by demonstrating an increase in both broad var gene expression and sexual commitment in parasites carrying deletions for key epigenetic regulator genes PfHP1 (Coleman et al. Reference Coleman, Skillman, Jiang, Childs, Altenhofen, Ganter, Leung, Goldowitz, Kafsack, Marti, Llinas, Buckee and Duraisingh2014) and PfHDA2 (Brancucci et al. Reference Brancucci, Bertschi, Zhu, Niederwieser, Chin, Wampfler, Freymond, Rottmann, Felger, Bozdech and Voss2014a). However, it is important to distinguish clearly between mechanistic and evolutionary links between virulence and transmissibility. The PfAP2-G gene recently found to be the gene responsible for immediate control of sexual commitment is flanked by insulator-like pairing elements that are also found in var genes, raising the possibility that sexual commitment and var gene expression are under common control to ensure their expression is mutually exclusive (Kafsack et al. Reference Kafsack, Rovira-Graells, Clark, Bancells, Crowley, Campino, Williams, Drought, Kwiatkowski, Baker, Cortes and Llinas2014).

Immunological studies of PfEMP1 domains

Five kinds of question need to be addressed in immunological and epidemiological studies to determine the extent to which different features of var genes are targets of naturally acquired immunity to malaria and/or potential vaccine candidates: (1) Are recombinant domains recognized broadly by naturally acquired antibodies or antibodies raised in animals? (2) Do antibodies raised in animals or adsorbed from human serum, bind to the surface of parasite infected erythrocytes, opsonise-infected erythrocytes or reverse cytoadhesion? (3) Is carriage of these antibodies associated with low frequency of future episodes of malaria or low severity of a current infection? (4) Is expression of the PfEMP1 feature by parasites in vivo negatively associated with host immunity measured as disease severity, IE antibodies carried at the time of infection or host age? (5) Are there conserved epitopes in PfEMP1 that can be targeted by antibodies? (6) Can antibodies be shown directly to protect against malaria?

Tables 1 and 2 together with Fig. 2 bring together some of the key information that has been gathered in relation to these questions. Considered alone these questions have important limitations. Question 1 does not distinguish between epitopes exposed by living or dead parasites. Question 3 carries the danger of confounding by cumulative exposure. Because of the diversity and immunogenicity of PfEMP1, recognition of various domains is likely to be excellent markers of past exposure, possibly better than the ‘exposure’ controls used.

Parasite expression levels in association with antibodies or age at the time of disease are likely to be a powerful approach to dissect specific components of the naturally acquired immune response. However, expression studies in parasites still rely heavily on indirect methods. Expression of DCs currently relies on qPCR using sets of primers that identify homology blocks within domains commonly encountered within specific DCs. It is important to note that this approach measures expression levels of specific DCs only indirectly and assumes that strong associations between homology blocks is maintained within the parasite population (Lavstsen et al. Reference Lavstsen, Turner, Saguti, Magistrado, Rask, Jespersen, Wang, Berger, Baraka, Marquard, Seguin-Orlando, Willerslev, Gilbert, Lusingu and Theander2012). Further information is needed on the stability of DCs over time and geographical space. To understand the effect of antibody selection on various different sequence features within var genes we urgently need complete sequence information from expressed var genes from parasites infecting children with different levels of naturally acquired antibodies. This will help us to fully understand why children succumb to life-threatening disease. To this end, a recent study has used mass spectrometry to identify sequence features related to DC8 in children with severe malaria (Bertin et al. Reference Bertin, Lavstsen, Guillonneau, Doritchamou, Wang, Jespersen, Ezimegnon, Fievet, Alao, Lalya, Massougbodji, Ndam, Theander and Deloron2013), but there are still only very few studies that have attempted to place var gene expression profiles at the time of severe malaria within the context of the immune response (Table 2).

A summary of attempts to directly address the challenge of developing a PfEMP1-based vaccine to childhood malaria

In this section, we will summarize the progress that has been made in direct attempts to address question 5 above and protect animals through vaccination with PfEMP1.

CD36-antibodies to CIDR

First attempts to raise cross-reactive antibodies to PfEMP1 focused on CD36-binding CIDR domains. The rationale for this was that the CIDR region, known to bind what was at the time the most prominent parasite receptor (CD36) was shown to be immunogenic and the target of antibodies that agglutinate parasites (Baruch et al. Reference Baruch, Ma, Singh, Bi, Pasloske and Howard1997). In the first study done through vaccination of Aotus monkeys with recombinant CD36-binding CIDR, there was cross-agglutination, and reactivity to recombinant CIDR, but this was not supported by surface labelling or reversal of CD36 binding (Gamain et al. Reference Gamain, Miller and Baruch2001). Using the Aotus Monkey model, Baruch and colleagues subsequently demonstrated that immunization with a single short region of the CD36-binding region of a single CIDR [r179 from the ‘Malayan Camp’ laboratory parasite line (Baruch et al. Reference Baruch, Ma, Singh, Bi, Pasloske and Howard1997)] can immunize against infection with the homologous strain (Baruch et al. Reference Baruch, Gamain, Barnwell, Sullivan, Stowers, Galland, Miller and Collins2002). This seemed to suggest that ‘determinant spreading’ (Lehmann et al. Reference Lehmann, Sercarz, Forsthuber, Dayan and Gammon1993) was occurring and that immunization with a non-immunodominant region boosts the development of cross-reactive antibodies. However, in this model in which monkeys were challenged directly with ring stage parasites, there is a clear first wave of infection that is dominated by a single variant, which may not model sporozoite challenge of humans (Wang et al. Reference Wang, Hermsen, Sauerwein, Arnot, Theander and Lavstsen2009). This may help explain why the vaccination did not protect against heterologous parasite isolates (Baruch et al. Reference Baruch, Gamain, Barnwell, Sullivan, Stowers, Galland, Miller and Collins2002). To favour the stimulation of cross-reactive antibodies, simultaneous vaccination of mice with three different proteins [MC CIDR1 (residues 1–267), FVO CIDR1 (residues 1–260) and A4tres CIDR1 (residues 1–262)] was used. This led to an increase in cross-recognition over separate vaccination (Gratepanche et al. Reference Gratepanche, Gamain, Smith, Robinson, Saul and Miller2003). However, such a regime did not protect Aotus from the virulent line FVO, despite some protection from anaemia (Makobongo et al. Reference Makobongo, Keegan, Long and Miller2006).

Antibodies to DBLalpha

DBLalpha domains are present within all PfEMP1 variants associated with childhood malaria and are therefore an attractive domain to target in a vaccine. However, raising antibodies that recognize the surface of infected erythrocyte has been a challenge. Initial studies on immunization with Escherichia coli expressed DBLalpha region lead to antibodies that recognize conserved regions of recombinant proteins but that do not recognize the surface of the infected erythrocytes (Oguariri et al. Reference Oguariri, Mattei, Tena-Tomas, Uhlemann, Kremsner and Kun2003; Chen et al. Reference Chen, Pettersson, Vogt, Schmidt, Ahuja, Liljestrom and Wahlgren2004). This problem was overcome by immunization with mini-var Semliki forest virus constructs that are displayed on the surface of virus-infected cells. The effectiveness of antibodies in reversing rosetting was tested using antibodies against DBLalpha from FCR3S1·2var1 (Chen et al. Reference Chen, Pettersson, Vogt, Schmidt, Ahuja, Liljestrom and Wahlgren2004) and a rat lung in vivo sequestration model was used to test for reversal of sequestration. The in vivo model using 99mtechnetium-labelled iRBC was also adapted for use in cynomolgus macaques and shown to be effective (Moll et al. Reference Moll, Pettersson, Vogt, Jonsson, Rasti, Ahuja, Spangberg, Mercereau-Puijalon, Arnot, Wahlgren and Chen2007) and led to a 46% reduction in sequestration against the homologous isolate. However, the var gene used in these studies was subsequently shown not to be involved in rosetting (Albrecht et al. Reference Albrecht, Moll, Blomqvist, Normark, Chen and Wahlgren2011) and the authors suggest that anti-rosetting activity was due to cross-reactivity.

The development of platforms for controlled human infection with malaria parasites are likely to allow rapid testing of vaccine candidates that has not been possible previously (Hodgson et al. Reference Hodgson, Juma, Salim, Magiri, Kimani, Njenga, Muia, Cole, Ogwang, Awuondo, Lowe, Munene, Billingsley, James, Gunasekera, Sim, Njuguna, Rampling, Richman, Abebe, Kamuyu, Muthui, Elias, Molyneux, Gerry, Macharia, Williams, Bull, Hill and Osier2014; Obiero et al. Reference Obiero, Shekalaghe, Hermsen, Mpina, Bijker, Roestenberg, Teelen, Billingsley, Sim, James, Daubenberger, Hoffman, Abdulla, Sauerwein and Scholzen2015).

Global approaches to finding important protective epitopes on PfEMP1

Using an entirely different approach, Blomqvist et al. (Reference Blomqvist, Albrecht, Quintana Mdel, Angeletti, Joannin, Chene, Moll and Wahlgren2013) used var gene expression data of parasites from Ugandan children to identify short stretches of PfEMP1 sequence that are associated with severe malaria (Normark et al. Reference Normark, Nilsson, Ribacke, Winter, Moll, Wheelock, Bayarugaba, Kironde, Egwang, Chen, Andersson and Wahlgren2007). They raised antibodies to peptides based around these motifs. One of these peptides called RDSM (respiratory distress severe malaria) containing the ALNRKE motif and associated with respiratory distress, stimulated production of antibodies that cross-reacted against several parasite lines including R29, whose expressed var gene (IT4 var9) contains the very similar AINRKE motif (Blomqvist et al. Reference Blomqvist, Albrecht, Quintana Mdel, Angeletti, Joannin, Chene, Moll and Wahlgren2013). This region is in a relatively conserved part of the molecule in the same region as another peptide from var2CSA that is associated with changes in sequence expression between primigravid and multigravid women (Dahlback et al. Reference Dahlback, Rask, Andersen, Nielsen, Ndam, Resende, Turner, Deloron, Hviid, Lund, Pedersen, Theander and Salanti2006).

Directing response to the conserved regions

As is the case with other highly diverse pathogens naturally acquired immune responses are most frequently directed towards the diverse immunodominant regions despite rare individuals who make substantial responses to conserved regions (Rathore et al. Reference Rathore, Kesavardhana, Mallajosyula and Varadarajan2014). In HIV, researchers are trying to tackle this problem by directing the immune response to the most conserved regions of the surface antigens. This they do by bringing together artificially the conserved regions of antigens into one composite antigen (Hanke, Reference Hanke2014). A similar approach has been explored for PfEMP1 by Patarroyo et al. (Reference Patarroyo, Alba, Curtidor, Vanegas, Almonacid and Patarroyo2014) who have initiated a high-throughput approach to screening 15–20aa long peptides for host cell binding [high activity binding peptides (HABPs)], immunogenicity and protective efficacy in Aotus. Their approach involves modifications of otherwise non-immunogenic regions within a single var gene (var2CSA from Dd2) to convert them into immunogenic peptides [modified HABPs (mHABPs)]. The most promising peptides are both located within homology block 4 (Rask et al. Reference Rask, Hansen, Theander, Gorm Pedersen and Lavstsen2010) and contain the GACxPxRRxxLC canonical motif (Patarroyo et al. Reference Patarroyo, Alba, Curtidor, Vanegas, Almonacid and Patarroyo2014).

Future directions

There have been some exciting recent developments in our understanding of the PfEMP1 family of surface antigens, but there are clearly challenges ahead.

Despite the plausible mechanism that would explain the pathology of cerebral malaria (Taylor et al. 2013) it is still unclear whether EPCR is a common receptor for parasites since only a relatively small number of clinical parasite isolates have so far been tested. A recent paper by Esser et al. (Reference Esser, Bachmann, Kuhn, Schuldt, Forster, Thiel, May, Koch-Nolte, Yanez-Mo, Sanchez-Madrid, Schinkel, Jalkanen, Craig, Bruchhaus and Horstmann2014) suggests the existence of a large number of possible novel host receptors for PfEMP1; however, it is not clear if any of these could sustain an infection at high parasitaemia.

Two recent reports suggest that on the one hand var expression may be under some level of global control (Merrick et al. Reference Merrick, Huttenhower, Buckee, Amambua-Ngwa, Gomez-Escobar, Walther, Conway and Duraisingh2012) and on the other hand, that two other gene families may be able to support sequestration (Niang et al. Reference Niang, Bei, Madnani, Pelly, Dankwa, Kanjee, Gunalan, Amaladoss, Yeo, Bob, Malleret, Duraisingh and Preiser2014; Goel et al. Reference Goel, Palmkvist, Moll, Joannin, Lara, Akhouri, Moradi, Ojemalm, Westman, Angeletti, Kjellin, Lehtio, Blixt, Idestrom, Gahmberg, Storry, Hult, Olsson, von Heijne, Nilsson and Wahlgren2015). PfEMP1 appears also to be partially controlled at the translational level (Brancucci et al. Reference Brancucci, Witmer, Schmid and Voss2014b). This raises the possibility that the parasite could diversify both the type and total amount of variant antigen expressed on the infected erythrocyte surface.

The important question here is whether the level of sequestration supported by STEVOR and RIFINs in the absence of PfEMP1 could support parasite loads associated with severe malaria. Though knockdowns of var have an important effect on the antigenic properties of laboratory isolates (Chan et al. Reference Chan, Howell, Reiling, Ataide, Mackintosh, Fowkes, Petter, Chesson, Langer, Warimwe, Duffy, Rogerson, Bull, Cowman, Marsh and Beeson2012), they may not fully model the behaviour of non-PfEMP1 VSA in vivo. Warimwe et al. (Reference Warimwe, Fegan, Musyoki, Newton, Opiyo, Githinji, Andisi, Menza, Kitsao, Marsh and Bull2012) observed an association between respiratory distress and rosetting in Kenya. Despite a strong overall association between rosetting and the expression of group A var genes, the observed association was independent of group A-like var gene expression or any other subgroup of var genes that could be identified. One possible interpretation of this is that the association between rosetting and respiratory distress was driven by a subset of parasites for which rosetting is mediated through RIFINs or STEVOR. This highlights the need for full sequence information of VSA expressed under different levels of naturally acquired immunity.

Future research on developing interventions based on PfEMP1 needs to continue to refine definitions of different cytoadhesive phenotypes at the molecular level. Various terms such as ‘rosetting’, ‘VSASM’, ‘group A PfEMP1’, ‘DC8’, in the same way as clinical definitions such as ‘cerebral malaria’ (Taylor et al. Reference Taylor, Fu, Carr, Whitten, Mueller, Fosiko, Lewallen, Liomba and Molyneux2004), are essential for generating hypotheses, but what they describe are potentially heterogeneous. More studies are still needed to directly link structure, cytoadhesive function and antigenicity with naturally acquired immunity to clearly defined malarial disease.

ACKNOWLEDGEMENT

This paper was published by the permission of the Director of the Kenya Medical Research Institute.

FINANCIAL SUPPORT

A.A. was supported by the Wellcome Trust Training grant in Public Health and Tropical Medicine (grant no. 103956) and a Wellcome Trust Strategic Award (grant no. 084538).

References

REFERENCES

Adams, Y., Kuhnrae, P., Higgins, M. K., Ghumra, A. and Rowe, J. A. (2014). Rosetting Plasmodium falciparum-infected erythrocytes bind to human brain microvascular endothelial cells in vitro, demonstrating a dual adhesion phenotype mediated by distinct P. falciparum erythrocyte membrane protein 1 domains. Infection and Immunity 82, 949959.CrossRefGoogle ScholarPubMed
Aguiar, J. C., Albrecht, G. R., Cegielski, P., Greenwood, B. M., Jensen, J. B., Lallinger, G., Martinez, A., McGregor, I. A., Minjas, J. N., Neequaye, J., Patarroyo, M. E., Sherwood, J. A. and Howard, R. J. (1992). Agglutination of Plasmodium falciparum-infected erythrocytes from east and west African isolates by human sera from distant geographical regions. American Journal of Tropical Medicine and Hygiene 47, 621632.CrossRefGoogle Scholar
Alano, P. (2014). The sound of sexual commitment breaks the silencing of malaria parasites. Trends in Parasitology 30, 509510.CrossRefGoogle ScholarPubMed
Albrecht, L., Moll, K., Blomqvist, K., Normark, J., Chen, Q. and Wahlgren, M. (2011). var gene transcription and PfEMP1 expression in the rosetting and cytoadhesive Plasmodium falciparum clone FCR3S1·2. Malaria Journal 10, 17.CrossRefGoogle ScholarPubMed
Albrecht, L., Angeletti, D., Moll, K., Blomqvist, K., Valentini, D., D'Alexandri, F. L., Maurer, M. and Wahlgren, M. (2014). B-Cell Epitopes in NTS-DBL1alpha of PfEMP1 Recognized by Human Antibodies in Rosetting Plasmodium falciparum. PLoS ONE 9, e113248.CrossRefGoogle ScholarPubMed
Almelli, T., Nuel, G., Bischoff, E., Aubouy, A., Elati, M., Wang, C. W., Dillies, M. A., Coppee, J. Y., Ayissi, G. N., Basco, L. K., Rogier, C., Ndam, N. T., Deloron, P. and Tahar, R. (2014). Differences in gene transcriptomic pattern of Plasmodium falciparum in children with cerebral malaria and asymptomatic carriers. PLoS ONE 9, e114401.CrossRefGoogle ScholarPubMed
Angeletti, D., Albrecht, L., Blomqvist, K., Quintana Mdel, P., Akhter, T., Bachle, S. M., Sawyer, A., Sandalova, T., Achour, A., Wahlgren, M. and Moll, K. (2012). Plasmodium falciparum rosetting epitopes converge in the SD3-loop of PfEMP1-DBL1alpha. PLoS ONE 7, e50758.CrossRefGoogle ScholarPubMed
Ankarklev, J., Brancucci, N. M., Goldowitz, I., Mantel, P. Y. and Marti, M. (2014). Sex: how malaria parasites get turned on. Current Biology 24, R368R370.CrossRefGoogle ScholarPubMed
Avril, M., Tripathi, A. K., Brazier, A. J., Andisi, C., Janes, J. H., Soma, V. L., Sullivan, D. J., Bull, P. C., Stins, M. F. and Smith, J. D. (2012). A restricted subset of var genes mediates adherence of Plasmodium falciparum-infected erythrocytes to brain endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 109, E1782E1790.Google ScholarPubMed
Barfod, L., Dalgaard, M. B., Pleman, S. T., Ofori, M. F., Pleass, R. J. and Hviid, L. (2011). Evasion of immunity to Plasmodium falciparum malaria by IgM masking of protective IgG epitopes in infected erythrocyte surface-exposed PfEMP1. Proceedings of the National Academy of Sciences of the United States of America 108, 1248512490.CrossRefGoogle ScholarPubMed
Barnwell, J. W., Howard, R. J., Coon, H. G. and Miller, L. H. (1983). Splenic requirement for antigenic variation and expession of the variant antigen on the erythrocyte membrane in cloned Plasmodium knowlesi malaria. Infection and Immunity 40, 985994.CrossRefGoogle Scholar
Barragan, A., Kremsner, P. G., Weiss, W., Wahlgren, M. and Carlson, J. (1998). Age-related buildup of humoral immunity against epitopes for rosette formation and agglutination in African areas of malaria endemicity. Infection and Immunity 66, 47834787.CrossRefGoogle ScholarPubMed
Barry, A. E., Leliwa-Sytek, A., Tavul, L., Imrie, H., Migot-Nabias, F., Brown, S. M., McVean, G. A. and Day, K. P. (2007). Population genomics of the immune evasion (var) genes of Plasmodium falciparum. PLoS Pathogens 3, e34.Google ScholarPubMed
Baruch, D. I., Pasloske, B. L., Singh, H. B., Bi, X., Ma, X. C., Feldman, M., Taraschi, T. F. and Howard, R. J. (1995). Cloning the Plasmodium falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 82, 7787.CrossRefGoogle ScholarPubMed
Baruch, D. I., Ma, X. C., Singh, H. B., Bi, X., Pasloske, B. L. and Howard, R. J. (1997). Identification of a region of PfEMP1 that mediates adherence of Plasmodium falciparum infected erythrocytes to CD36: conserved function with variant sequence. Blood 90, 37663775.CrossRefGoogle ScholarPubMed
Baruch, D. I., Gamain, B., Barnwell, J. W., Sullivan, J. S., Stowers, A., Galland, G. G., Miller, L. H. and Collins, W. E. (2002). Immunization of Aotus monkeys with a functional domain of the Plasmodium falciparum variant antigen induces protection against a lethal parasite line. Proceedings of the National Academy of Sciences of the United States of America 99, 38603865.CrossRefGoogle ScholarPubMed
Beeson, J. G., Brown, G. V., Molyneux, M. E., Mhango, C., Dzinjalamala, F. and Rogerson, S. J. (1999). Plasmodium falciparum isolates from infected pregnant women and children are associated with distinct adhesive and antigenic properties. Journal of Infectious Diseases 180, 464472.CrossRefGoogle ScholarPubMed
Bengtsson, A., Joergensen, L., Rask, T. S., Olsen, R. W., Andersen, M. A., Turner, L., Theander, T. G., Hviid, L., Higgins, M. K., Craig, A., Brown, A. and Jensen, A. T. (2013). A novel domain cassette identifies Plasmodium falciparum PfEMP1 proteins binding ICAM-1 and is a target of cross-reactive, adhesion-inhibitory antibodies. Journal of Immunology 190, 240249.CrossRefGoogle ScholarPubMed
Berger, S. S., Turner, L., Wang, C. W., Petersen, J. E., Kraft, M., Lusingu, J. P., Mmbando, B., Marquard, A. M., Bengtsson, D. B., Hviid, L., Nielsen, M. A., Theander, T. G. and Lavstsen, T. (2013). Plasmodium falciparum expressing domain cassette 5 type PfEMP1 (DC5-PfEMP1) bind PECAM1. PLoS ONE 8, e69117.CrossRefGoogle ScholarPubMed
Bertin, G. I., Lavstsen, T., Guillonneau, F., Doritchamou, J., Wang, C. W., Jespersen, J. S., Ezimegnon, S., Fievet, N., Alao, M. J., Lalya, F., Massougbodji, A., Ndam, N. T., Theander, T. G. and Deloron, P. (2013). Expression of the domain cassette 8 Plasmodium falciparum erythrocyte membrane protein 1 is associated with cerebral malaria in Benin. PLoS ONE 8, e68368.CrossRefGoogle ScholarPubMed
Bigey, P., Gnidehou, S., Doritchamou, J., Quiviger, M., Viwami, F., Couturier, A., Salanti, A., Nielsen, M. A., Scherman, D., Deloron, P. and Tuikue Ndam, N. (2011). The NTS-DBL2X region of VAR2CSA induces cross-reactive antibodies that inhibit adhesion of several Plasmodium falciparum isolates to chondroitin sulfate A. Journal of Infectious Diseases 204, 11251133.CrossRefGoogle ScholarPubMed
Biggs, B. A., Gooze, L., Wycherley, K., Wollish, W., Southwell, B., Leech, J. H. and Brown, G. V. (1991). Antigenic variation in Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America 88, 91719174.CrossRefGoogle ScholarPubMed
Blomqvist, K., Albrecht, L., Quintana Mdel, P., Angeletti, D., Joannin, N., Chene, A., Moll, K. and Wahlgren, M. (2013). A sequence in subdomain 2 of DBL1alpha of Plasmodium falciparum erythrocyte membrane protein 1 induces strain transcending antibodies. PLoS ONE 8, e52679.CrossRefGoogle ScholarPubMed
Bordbar, B., Tuikue-Ndam, N., Bigey, P., Doritchamou, J., Scherman, D. and Deloron, P. (2012). Identification of Id1-DBL2X of VAR2CSA as a key domain inducing highly inhibitory and cross-reactive antibodies. Vaccine 30, 13431348.CrossRefGoogle ScholarPubMed
Brancucci, N. M., Bertschi, N. L., Zhu, L., Niederwieser, I., Chin, W. H., Wampfler, R., Freymond, C., Rottmann, M., Felger, I., Bozdech, Z. and Voss, T. S. (2014 a). Heterochromatin protein 1 secures survival and transmission of malaria parasites. Cell Host Microbe 16, 165176.CrossRefGoogle ScholarPubMed
Brancucci, N. M., Witmer, K., Schmid, C. and Voss, T. S. (2014 b). A var gene upstream element controls protein synthesis at the level of translation initiation in Plasmodium falciparum. PLoS ONE 9, e100183.CrossRefGoogle ScholarPubMed
Buckee, C. O. and Recker, M. (2012). Evolution of the multi-domain structures of virulence genes in the human malaria parasite, Plasmodium falciparum. PLoS Computational Biology 8, e1002451.CrossRefGoogle ScholarPubMed
Bull, P. C., Lowe, B. S., Kortok, M., Molyneux, C. S., Newbold, C. I. and Marsh, K. (1998). Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nature Medicine 4, 358360.CrossRefGoogle ScholarPubMed
Bull, P. C., Lowe, B. S., Kortok, M. and Marsh, K. (1999). Antibody recognition of Plasmodium falciparum erythrocyte surface antigens in Kenya: evidence for rare and prevalent variants. Infection and Immunity 67, 733739.CrossRefGoogle ScholarPubMed
Bull, P. C., Kortok, M., Kai, O., Ndungu, F., Ross, A., Lowe, B. S., Newbold, C. I. and Marsh, K. (2000). Plasmodium falciparum-infected erythrocytes: agglutination by diverse Kenyan plasma is associated with severe disease and young host age. Journal of Infectious Diseases 182, 252259.CrossRefGoogle Scholar
Bull, P. C., Lowe, B. S., Kaleli, N., Njuga, F., Kortok, M., Ross, A., Ndungu, F., Snow, R. W. and Marsh, K. (2002). Plasmodium falciparum infections are associated with agglutinating antibodies to parasite infected erythrocyte surface antigens among healthy Kenyan children. Journal of Infectious Diseases 185, 16881691.CrossRefGoogle ScholarPubMed
Bull, P. C., Berriman, M., Kyes, S., Quail, M. A., Hall, N., Kortok, M. M., Marsh, K. and Newbold, C. I. (2005 a). Plasmodium falciparum variant surface antigen expression patterns during malaria. PLoS Pathogens 1, e26.CrossRefGoogle ScholarPubMed
Bull, P. C., Pain, A., Ndungu, F. M., Kinyanjui, S. M., Roberts, D. J., Newbold, C. I. and Marsh, K. (2005 b). Plasmodium falciparum antigenic variation: relationships between in-vivo selection, the acquired antibody response and disease severity. Journal of Infectious Diseases 192, 11191126.CrossRefGoogle ScholarPubMed
Bull, P. C., Buckee, C. O., Kyes, S., Kortok, M. M., Thathy, V., Guyah, B., Stoute, J. A., Newbold, C. I. and Marsh, K. (2008). Plasmodium falciparum antigenic variation. Mapping mosaic var gene sequences onto a network of shared, highly polymorphic sequence blocks. Molecular Microbiology 68, 15191534.CrossRefGoogle ScholarPubMed
Carlson, J., Helmby, H., Hill, A. V. S., Brewster, D., Greenwood, B. M. and Wahlgren, M. M. (1990). Human cerebral malaria: association with erythrocyte rosetting and lack of anti-rosetting antibodies. The Lancet 336, 14571460.CrossRefGoogle ScholarPubMed
Cham, G. K., Turner, L., Lusingu, J., Vestergaard, L., Mmbando, B. P., Kurtis, J. D., Jensen, A. T., Salanti, A., Lavstsen, T. and Theander, T. G. (2009). Sequential, ordered acquisition of antibodies to Plasmodium falciparum erythrocyte membrane protein 1 domains. Journal of Immunology 183, 33563363.CrossRefGoogle ScholarPubMed
Cham, G. K., Turner, L., Kurtis, J. D., Mutabingwa, T., Fried, M., Jensen, A. T., Lavstsen, T., Hviid, L., Duffy, P. E. and Theander, T. G. (2010). Hierarchical, domain type-specific acquisition of antibodies to Plasmodium falciparum erythrocyte membrane protein 1 in Tanzanian children. Infection and Immunity 78, 46534659.CrossRefGoogle ScholarPubMed
Chan, J. A., Howell, K. B., Reiling, L., Ataide, R., Mackintosh, C. L., Fowkes, F. J., Petter, M., Chesson, J. M., Langer, C., Warimwe, G. M., Duffy, M. F., Rogerson, S. J., Bull, P. C., Cowman, A. F., Marsh, K. and Beeson, J. G. (2012). Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. Journal of Clinical Investigation 122, 32273238.CrossRefGoogle ScholarPubMed
Chan, J. A., Fowkes, F. J. and Beeson, J. G. (2014). Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates. Cellular and Molecular Life Sciences 71, 36333657.CrossRefGoogle ScholarPubMed
Chen, Q., Pettersson, F., Vogt, A. M., Schmidt, B., Ahuja, S., Liljestrom, P. and Wahlgren, M. (2004). Immunization with PfEMP1-DBL1alpha generates antibodies that disrupt rosettes and protect against the sequestration of Plasmodium falciparum-infected erythrocytes. Vaccine 22, 27012712.CrossRefGoogle ScholarPubMed
Cheng, Q., Cloonan, N., Fischer, K., Thompson, J., Waine, G., Lanzer, M. and Saul, A. (1998). stevor and rif are Plasmodium falciparum multicopy gene families which potentially encode variant antigens. Molecular and Biochemical Parasitology 97, 161176.CrossRefGoogle ScholarPubMed
Claessens, A., Adams, Y., Ghumra, A., Lindergard, G., Buchan, C. C., Andisi, C., Bull, P. C., Mok, S., Gupta, A. P. and Wang, C. W. (2012). A subset of group A-like var genes encodes the malaria parasite ligands for binding to human brain endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 109, E1772E1781.Google ScholarPubMed
Claessens, A., Hamilton, W. L., Kekre, M., Otto, T. D., Faizullabhoy, A., Rayner, J. C. and Kwiatkowski, D. (2014). Generation of antigenic diversity in Plasmodium falciparum by structured rearrangement of var genes during mitosis. PLoS Genetics 10, e1004812.CrossRefGoogle ScholarPubMed
Clausen, T. M., Christoffersen, S., Dahlback, M., Langkilde, A. E., Jensen, K. E., Resende, M., Agerbaek, M. O., Andersen, D., Berisha, B., Ditlev, S. B., Pinto, V. V., Nielsen, M. A., Theander, T. G., Larsen, S. and Salanti, A. (2012). Structural and functional insight into how the Plasmodium falciparum VAR2CSA protein mediates binding to chondroitin sulfate A in placental malaria. Journal of Biological Chemistry 287, 2333223345.CrossRefGoogle ScholarPubMed
Coleman, B. I., Skillman, K. M., Jiang, R. H., Childs, L. M., Altenhofen, L. M., Ganter, M., Leung, Y., Goldowitz, I., Kafsack, B. F., Marti, M., Llinas, M., Buckee, C. O. and Duraisingh, M. T. (2014). A Plasmodium falciparum histone deacetylase regulates antigenic variation and gametocyte conversion. Cell Host Microbe 16, 177186.CrossRefGoogle ScholarPubMed
Dahlback, M., Rask, T. S., Andersen, P. H., Nielsen, M. A., Ndam, N. T., Resende, M., Turner, L., Deloron, P., Hviid, L., Lund, O., Pedersen, A. G., Theander, T. G. and Salanti, A. (2006). Epitope mapping and topographic analysis of VAR2CSA DBL3X involved in P. falciparum placental sequestration. PLoS Pathogens 2, e124.CrossRefGoogle Scholar
de Boer, R. J. and Boerlijst, M. C. (1994). Diversity and virulence thresholds in AIDS. Proceedings of the National Academy of Sciences of the United States of America 91, 544548.CrossRefGoogle ScholarPubMed
Dodoo, D., Staalsoe, T., Giha, H., Kurtzhals, J. A., Akanmori, B. D., Koram, K., Dunyo, S., Nkrumah, F. K., Hviid, L. and Theander, T. G. (2001). Antibodies to variant antigens on the surfaces of infected erythrocytes are associated with protection from malaria in Ghanaian children. Infection and Immunity 69, 37133718.CrossRefGoogle ScholarPubMed
Doritchamou, J., Bigey, P., Nielsen, M. A., Gnidehou, S., Ezinmegnon, S., Burgain, A., Massougbodji, A., Deloron, P., Salanti, A. and Ndam, N. T. (2013). Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA. Vaccine 31, 45164522.CrossRefGoogle ScholarPubMed
Esser, C., Bachmann, A., Kuhn, D., Schuldt, K., Forster, B., Thiel, M., May, J., Koch-Nolte, F., Yanez-Mo, M., Sanchez-Madrid, F., Schinkel, A. H., Jalkanen, S., Craig, A. G., Bruchhaus, I. and Horstmann, R. D. (2014). Evidence of promiscuous endothelial binding by Plasmodium falciparum-infected erythrocytes. Cellular Microbiology 16, 701708.CrossRefGoogle ScholarPubMed
Falk, N., Kaestli, M., Qi, W., Ott, M., Baea, K., Cortes, A. and Beck, H. P. (2009). Analysis of Plasmodium falciparum var genes expressed in children from Papua New Guinea. Journal of Infectious Diseases 200, 347356.CrossRefGoogle ScholarPubMed
Fernandez, V., Hommel, M., Chen, Q., Hagblom, P. and Wahlgren, M. (1999). Small, clonally variant antigens expressed on the surface of the Plasmodium falciparum-infected erythrocyte are encoded by the rif gene family and are the target of human immune responses. Journal of Experimental Medicine 190, 13931404.CrossRefGoogle ScholarPubMed
Forsyth, K. P., Philip, G., Smith, T., Kum, E., Southwell, B. and Brown, G. V. (1989). Diversity of antigens expressed on the surface of erythrocytes infected with mature Plasmodium falciparum parasites in Papua New Guinea. American Journal of Tropical Medicine and Hygiene 41, 259265.CrossRefGoogle ScholarPubMed
Frank, S. A. and Bush, R. M. (2007). Barriers to antigenic escape by pathogens: trade-off between reproductive rate and antigenic mutability. BMC Evolutionary Biology 7, 229.CrossRefGoogle ScholarPubMed
Gamain, B., Miller, L. H. and Baruch, D. I. (2001). The surface variant antigens of Plasmodium falciparum contain cross-reactive epitopes. Proceedings of the National Academy of Sciences of the United States of America 98, 26642669.CrossRefGoogle ScholarPubMed
Gardner, M. J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R. W., Carlton, J. M., Pain, A., Nelson, K. E., Bowman, S., Paulsen, I. T., James, K., Eisen, J. A., Rutherford, K., Salzberg, S. L., Craig, A., Kyes, S., Chan, M. S., Nene, V., Shallom, S. J., Suh, B., Peterson, J., Angiuoli, S., Pertea, M., Allen, J., Selengut, J., Haft, D., Mather, M. W., Vaidya, A. B., Martin, D. M. et al. (2002). Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419, 498511.CrossRefGoogle ScholarPubMed
Ghumra, A., Semblat, J. P., McIntosh, R. S., Raza, A., Rasmussen, I. B., Braathen, R., Johansen, F. E., Sandlie, I., Mongini, P. K., Rowe, J. A. and Pleass, R. J. (2008). Identification of residues in the Cmu4 domain of polymeric IgM essential for interaction with Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). Journal of Immunology 181, 19882000.CrossRefGoogle ScholarPubMed
Ghumra, A., Semblat, J.-P., Ataide, R., Kifude, C., Adams, Y., Claessens, A., Anong, D. N., Bull, P. C., Fennell, C. and Arman, M. (2012). Induction of strain-transcending antibodies against Group A PfEMP1 surface antigens from virulent malaria parasites. PLoS Pathogens 8, e1002665.CrossRefGoogle Scholar
Giha, H. A., Staalsoe, T., Dodoo, D., Roper, C., Satti, G. M., Arnot, D. E., Hviid, L. and Theander, T. G. (2000). Antibodies to variable Plasmodium falciparum-infected erythrocyte surface antigens are associated with protection from novel malaria infections. Immunology Letters 71, 117126.CrossRefGoogle ScholarPubMed
Goel, S., Palmkvist, M., Moll, K., Joannin, N., Lara, P., Akhouri, R., Moradi, R., Ojemalm, K., Westman, M., Angeletti, D., Kjellin, H., Lehtio, J., Blixt, O., Idestrom, L., Gahmberg, C. G., Storry, J. R., Hult, A. K., Olsson, M. L., von Heijne, G., Nilsson, I. and Wahlgren, M. (2015). RIFINs are adhesins implicated in severe Plasmodium falciparum malaria. Nature Medicine 21, 314317.CrossRefGoogle ScholarPubMed
Goncalves, B. P., Huang, C. Y., Morrison, R., Holte, S., Kabyemela, E., Prevots, D. R., Fried, M. and Duffy, P. E. (2014). Parasite burden and severity of malaria in Tanzanian children. New England Journal of Medicine 370, 17991808.CrossRefGoogle ScholarPubMed
Gratepanche, S., Gamain, B., Smith, J. D., Robinson, B. A., Saul, A. and Miller, L. H. (2003). Induction of crossreactive antibodies against the Plasmodium falciparum variant protein. Proceedings of the National Academy of Sciences of the United States of America 100, 1300713012.CrossRefGoogle ScholarPubMed
Greenwood, B., Marsh, K. and Snow, R. (1991). Why do some African Children develop severe malaria. Parasitology Today 7, 277281.CrossRefGoogle ScholarPubMed
Griffin, J. T., Hollingsworth, T. D., Reyburn, H., Drakeley, C. J., Riley, E. M. and Ghani, A. C. (2015). Gradual acquisition of immunity to severe malaria with increasing exposure. Proceedings of the Royal Society of London Series B 282, 20142657.Google ScholarPubMed
Gupta, S., Snow, R. W., Donnelly, C. and Newbold, C. (1999 a). Acquired immunity and postnatal clinical protection in childhood cerebral malaria. Proceedings of the Royal Society of London Series B 266, 3338.CrossRefGoogle ScholarPubMed
Gupta, S., Snow, R. W., Donnelly, C. A., Marsh, K. and Newbold, C. (1999 b). Immunity to non-cerebral severe malaria is acquired after one or two infections. Nature Medicine 5, 340343.CrossRefGoogle ScholarPubMed
Hanke, T. (2014). Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines. Expert Opinion on Biological Therapy 14, 601616.CrossRefGoogle ScholarPubMed
Hayward, R. E., Tiwari, B., Piper, K. P., Baruch, D. I. and Day, K. P. (1999). Virulence and transmission success of the malarial parasite Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America 96, 45634568.CrossRefGoogle ScholarPubMed
Heddini, A., Pettersson, F., Kai, O., Shafi, J., Obiero, J., Chen, Q., Barragan, A., Wahlgren, M. and Marsh, K. (2001). Fresh isolates from children with severe Plasmodium falciparum malaria bind to multiple receptors. Infection and Immunity 69, 58495856.CrossRefGoogle ScholarPubMed
Higgins, M. K. and Carrington, M. (2014). Sequence variation and structural conservation allows development of novel function and immune evasion in parasite surface protein families. Protein Science 23, 354365.CrossRefGoogle ScholarPubMed
Hodgson, S. H., Juma, E., Salim, A., Magiri, C., Kimani, D., Njenga, D., Muia, A., Cole, A. O., Ogwang, C., Awuondo, K., Lowe, B., Munene, M., Billingsley, P. F., James, E. R., Gunasekera, A., Sim, B. K., Njuguna, P., Rampling, T. W., Richman, A., Abebe, Y., Kamuyu, G., Muthui, M., Elias, S. C., Molyneux, S., Gerry, S., Macharia, A., Williams, T. N., Bull, P. C., Hill, A. V., Osier, F. H. et al. (2014). Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Frontiers in Microbiology 5, 686.CrossRefGoogle ScholarPubMed
Iqbal, J., Perlmann, P. and Berzins, K. (1993). Serological diversity of antigens expressed on the surface of erythrocytes infected with Plasmodium falciparum. Transactions of the Royal Society of Tropical Medicine and Hygiene 87, 583588.CrossRefGoogle ScholarPubMed
Janes, J. H., Wang, C. P., Levin-Edens, E., Vigan-Womas, I., Guillotte, M., Melcher, M., Mercereau-Puijalon, O. and Smith, J. D. (2011). Investigating the host binding signature on the Plasmodium falciparum PfEMP1 protein family. PLoS Pathogens 7, e1002032.CrossRefGoogle ScholarPubMed
Jensen, A. T., Magistrado, P., Sharp, S., Joergensen, L., Lavstsen, T., Chiucchiuini, A., Salanti, A., Vestergaard, L. S., Lusingu, J. P., Hermsen, R., Sauerwein, R., Christensen, J., Nielsen, M. A., Hviid, L., Sutherland, C., Staalsoe, T. and Theander, T. G. (2004). Plasmodium falciparum associated with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes. Journal of Experimental Medicine 199, 11791190.CrossRefGoogle Scholar
Joergensen, L., Turner, L., Magistrado, P., Dahlback, M. A., Vestergaard, L. S., Lusingu, J. P., Lemnge, M., Salanti, A., Theander, T. G. and Jensen, A. T. (2006). Limited cross-reactivity among domains of the Plasmodium falciparum clone 3D7 erythrocyte membrane protein 1 family. Infection and Immunity 74, 67786784.CrossRefGoogle ScholarPubMed
Joergensen, L., Vestergaard, L. S., Turner, L., Magistrado, P., Lusingu, J. P., Lemnge, M., Theander, T. G. and Jensen, A. T. (2007). 3D7-Derived Plasmodium falciparum erythrocyte membrane protein 1 is a frequent target of naturally acquired antibodies recognizing protein domains in a particular pattern independent of malaria transmission intensity. Journal of Immunology 178, 428435.CrossRefGoogle Scholar
Kaestli, M., Cockburn, I. A., Cortes, A., Baea, K., Rowe, J. A. and Beck, H. P. (2006). Virulence of malaria is associated with differential expression of Plasmodium falciparum var gene subgroups in a case-control study. Journal of Infectious Diseases 193, 15671574.CrossRefGoogle ScholarPubMed
Kafsack, B. F., Rovira-Graells, N., Clark, T. G., Bancells, C., Crowley, V. M., Campino, S. G., Williams, A. E., Drought, L. G., Kwiatkowski, D. P., Baker, D. A., Cortes, A. and Llinas, M. (2014). A transcriptional switch underlies commitment to sexual development in malaria parasites. Nature 507, 248252.CrossRefGoogle ScholarPubMed
Kalmbach, Y., Rottmann, M., Kombila, M., Kremsner, P. G., Beck, H. P. and Kun, J. F. (2010). Differential var gene expression in children with malaria and antidromic effects on host gene expression. Journal of Infectious Diseases 202, 313317.CrossRefGoogle ScholarPubMed
Karamanou, M., Liappas, I., Antoniou, C., Androutsos, G. and Lykouras, E. (2013). Julius Wagner-Jauregg (1857–1940): introducing fever therapy in the treatment of neurosyphilis. Psychiatriki 24, 208212.Google Scholar
Kinyanjui, S. M., Mwangi, T., Bull, P. C., Newbold, C. I. and Marsh, K. (2004). Protection against clinical malaria by heterologous immunoglobulin G antibodies against malaria-infected erythrocyte variant surface antigens requires interaction with asymptomatic infections. Journal of Infectious Diseases 190, 15271533.CrossRefGoogle ScholarPubMed
Kirchgatter, K. and Portillo Hdel, A. (2002). Association of severe noncerebral Plasmodium falciparum malaria in Brazil with expressed PfEMP1 DBL1 alpha sequences lacking cysteine residues. Molecular Medicine 8, 1623.CrossRefGoogle ScholarPubMed
Klein, J. and O'Huigin, C. (1994). MHC polymorphism and parasites. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 346, 351357; discussion 357–358.Google ScholarPubMed
Klein, M. M., Gittis, A. G., Su, H. P., Makobongo, M. O., Moore, J. M., Singh, S., Miller, L. H. and Garboczi, D. N. (2008). The cysteine-rich interdomain region from the highly variable plasmodium falciparum erythrocyte membrane protein-1 exhibits a conserved structure. PLoS Pathogens 4, e1000147.CrossRefGoogle ScholarPubMed
Kraemer, S. M. and Smith, J. D. (2003). Evidence for the importance of genetic structuring to the structural and functional specialization of the Plasmodium falciparum var gene family. Molecular Microbiology 50, 15271538.CrossRefGoogle Scholar
Kraemer, S. M., Kyes, S. A., Aggarwal, G., Springer, A. L., Nelson, S. O., Christodoulou, Z., Smith, L. M., Wang, W., Levin, E., Newbold, C. I., Myler, P. J. and Smith, J. D. (2007). Patterns of gene recombination shape var gene repertoires in Plasmodium falciparum: comparisons of geographically diverse isolates. BMC Genomics 8, 45.CrossRefGoogle ScholarPubMed
Kyes, S. A., Rowe, J. A., Kriek, N. and Newbold, C. I. (1999). Rifins: a second family of clonally variant proteins expressed on the surface of red cells infected with Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America 96, 93339338.CrossRefGoogle ScholarPubMed
Kyriacou, H. M., Stone, G. N., Challis, R. J., Raza, A., Lyke, K. E., Thera, M. A., Kone, A. K., Doumbo, O. K., Plowe, C. V. and Rowe, J. A. (2006). Differential var gene transcription in Plasmodium falciparum isolates from patients with cerebral malaria compared to hyperparasitaemia. Molecular and Biochemical Parasitology 150, 211218.CrossRefGoogle ScholarPubMed
Lambert, L. H., Bullock, J. L., Cook, S. T., Miura, K., Garboczi, D. N., Diakite, M., Fairhurst, R. M., Singh, K. and Long, C. A. (2014). Antigen reversal identifies targets of opsonizing IgGs against pregnancy-associated malaria. Infection and Immunity 82, 48424853.CrossRefGoogle ScholarPubMed
Langhorne, J., Ndungu, F. M., Sponaas, A. M. and Marsh, K. (2008). Immunity to malaria: more questions than answers. Nature Immunology 9, 725732.CrossRefGoogle ScholarPubMed
Langreth, S. G. and Reese, R. T. (1979). Antigenicity of the infected-erythrocyte and merozoite surfaces in Falciparum malaria. Journal of Experimental Medicine 150, 12411254.CrossRefGoogle ScholarPubMed
Lau, C. K., Turner, L., Jespersen, J. S., Lowe, E. D., Petersen, B., Wang, C. W., Petersen, J. E., Lusingu, J., Theander, T. G., Lavstsen, T. and Higgins, M. K. (2015). Structural conservation despite huge sequence diversity allows EPCR binding by the PfEMP1 family implicated in severe childhood malaria. Cell Host Microbe 17, 118129.CrossRefGoogle ScholarPubMed
Lavstsen, T., Salanti, A., Jensen, A. T., Arnot, D. E. and Theander, T. G. (2003). Sub-grouping of Plasmodium falciparum 3D7 var genes based on sequence analysis of coding and non-coding regions. Malaria Journal 2, 27.CrossRefGoogle ScholarPubMed
Lavstsen, T., Turner, L., Saguti, F., Magistrado, P., Rask, T. S., Jespersen, J. S., Wang, C. W., Berger, S. S., Baraka, V., Marquard, A. M., Seguin-Orlando, A., Willerslev, E., Gilbert, M. T., Lusingu, J. and Theander, T. G. (2012). Plasmodium falciparum erythrocyte membrane protein 1 domain cassettes 8 and 13 are associated with severe malaria in children. Proceedings of the National Academy of Sciences of the United States of America 109, E1791E1800.Google ScholarPubMed
Lehmann, P. V., Sercarz, E. E., Forsthuber, T., Dayan, C. M. and Gammon, G. (1993). Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunology Today 14, 203208.CrossRefGoogle ScholarPubMed
Mackinnon, M. J. and Read, A. F. (2004). Virulence in malaria: an evolutionary viewpoint. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 359, 965986.CrossRefGoogle ScholarPubMed
Mackintosh, C. L., Mwangi, T., Kinyanjui, S. M., Mosobo, M., Pinches, R., Williams, T. N., Newbold, C. I. and Marsh, K. (2008). Failure to respond to the surface of Plasmodium falciparum infected erythrocytes predicts susceptibility to clinical malaria amongst African children. International Journal of Parasitology 38, 14451454.CrossRefGoogle Scholar
Magistrado, P. A., Lusingu, J., Vestergaard, L. S., Lemnge, M., Lavstsen, T., Turner, L., Hviid, L., Jensen, A. T. and Theander, T. G. (2007). Immunoglobulin G antibody reactivity to a group A Plasmodium falciparum erythrocyte membrane protein 1 and protection from P. falciparum malaria. Infection and Immunity 75, 24152420.CrossRefGoogle Scholar
Makobongo, M. O., Keegan, B., Long, C. A. and Miller, L. H. (2006). Immunization of Aotus monkeys with recombinant cysteine-rich interdomain region 1 alpha protects against severe disease during Plasmodium falciparum reinfection. Journal of Infectious Diseases 193, 731740.CrossRefGoogle ScholarPubMed
Marchiafava, E. and Bignami, A. (1894). On summer-autumn malaria fevers. In Two Monographs on Malaria and the Parasites of Malarial Fevers (ed. Marchiafava, E.), pp. 1232. New Sydenham Society, London.Google Scholar
Marsh, K. (1992). Malaria-a neglected disease? Parasitology, 104, S53S69.CrossRefGoogle ScholarPubMed
Marsh, K. and Howard, R. J. (1986). Antigens induced on erythrocytes by Plasmodium falciparum: expression of diverse and conserved determinants. Science 231, 150153.CrossRefGoogle ScholarPubMed
Marsh, K., Otoo, L., Hayes, R. J., Carson, D. C. and Greenwood, B. M. (1989).Antibodies to blood stage antigens of Plasmodium falciparum in rural gambians and their relation to protection against infection. Transactions of the Royal Society of Tropical Medicine and Hygiene 83, 293303.CrossRefGoogle ScholarPubMed
Merrick, C. J., Huttenhower, C., Buckee, C., Amambua-Ngwa, A., Gomez-Escobar, N., Walther, M., Conway, D. J. and Duraisingh, M. T. (2012). Epigenetic dysregulation of virulence gene expression in severe Plasmodium falciparum malaria. Journal of Infectious Diseases 205, 15931600.CrossRefGoogle ScholarPubMed
Molineaux, L., Diebner, H. H., Eichner, M., Collins, W. E., Jeffery, G. M. and Dietz, K. (2001). Plasmodium falciparum parasitaemia described by a new mathematical model. Parasitology 122, 379391.CrossRefGoogle ScholarPubMed
Moll, K., Pettersson, F., Vogt, A. M., Jonsson, C., Rasti, N., Ahuja, S., Spangberg, M., Mercereau-Puijalon, O., Arnot, D. E., Wahlgren, M. and Chen, Q. (2007). Generation of cross-protective antibodies against Plasmodium falciparum sequestration by immunization with an erythrocyte membrane protein 1-duffy binding-like 1 alpha domain. Infection and Immunity 75, 211219.CrossRefGoogle ScholarPubMed
Moxon, C. A., Wassmer, S. C., Milner, D. A. Jr., Chisala, N. V., Taylor, T. E., Seydel, K. B., Molyneux, M. E., Faragher, B., Esmon, C. T., Downey, C., Toh, C. H., Craig, A. G. and Heyderman, R. S. (2013). Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood 122, 842851.CrossRefGoogle ScholarPubMed
Newbold, C., Warn, P., Black, G., Berendt, A., Craig, A., Snow, B., Msobo, M., Peshu, N. and Marsh, K. (1997). Receptor-specific adhesion and clinical disease in Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene 57, 389398.CrossRefGoogle ScholarPubMed
Niang, M., Bei, A. K., Madnani, K. G., Pelly, S., Dankwa, S., Kanjee, U., Gunalan, K., Amaladoss, A., Yeo, K. P., Bob, N. S., Malleret, B., Duraisingh, M. T. and Preiser, P. R. (2014). STEVOR is a Plasmodium falciparum erythrocyte binding protein that mediates merozoite invasion and rosetting. Cell Host Microbe 16, 8193.CrossRefGoogle ScholarPubMed
Nielsen, M. A., Staalsoe, T., Kurtzhals, J. A., Goka, B. Q., Dodoo, D., Alifrangis, M., Theander, T. G., Akanmori, B. D. and Hviid, L. (2002). Plasmodium falciparum variant surface antigen expression varies between isolates causing severe and nonsevere malaria and is modified by acquired immunity. Journal of Immunology 168, 34443450.CrossRefGoogle ScholarPubMed
Nielsen, M. A., Vestergaard, L. S., Lusingu, J., Kurtzhals, J. A., Giha, H. A., Grevstad, B., Goka, B. Q., Lemnge, M. M., Jensen, J. B., Akanmori, B. D., Theander, T. G., Staalsoe, T. and Hviid, L. (2004). Geographical and temporal conservation of antibody recognition of Plasmodium falciparum variant surface antigens. Infection and Immunity 72, 35313535.CrossRefGoogle ScholarPubMed
Normark, J., Nilsson, D., Ribacke, U., Winter, G., Moll, K., Wheelock, C. E., Bayarugaba, J., Kironde, F., Egwang, T. G., Chen, Q., Andersson, B. and Wahlgren, M. (2007). PfEMP1-DBL1alpha amino acid motifs in severe disease states of Plasmodium falciparum malaria. Proceedings of the National Academy of Sciences of the United States of America 104, 1583515840.CrossRefGoogle ScholarPubMed
Nunes-Silva, S., Gangnard, S., Vidal, M., Vuchelen, A., Dechavanne, S., Chan, S., Pardon, E., Steyaert, J., Ramboarina, S., Chene, A. and Gamain, B. (2014). Llama immunization with full-length VAR2CSA generates cross-reactive and inhibitory single-domain antibodies against the DBL1X domain. Scientific Reports 4, 7373.CrossRefGoogle ScholarPubMed
Obiero, J. M., Shekalaghe, S., Hermsen, C. C., Mpina, M., Bijker, E. M., Roestenberg, M., Teelen, K., Billingsley, P. F., Sim, B. K., James, E. R., Daubenberger, C. A., Hoffman, S. L., Abdulla, S., Sauerwein, R. W. and Scholzen, A. (2015). Impact of malaria pre-exposure on anti-parasite cellular and humoral immune responses after controlled human malaria infection. Infection and Immunity 83, 21852196.CrossRefGoogle Scholar
Ochola, L. B., Siddondo, B. R., Ocholla, H., Nkya, S., Kimani, E. N., Williams, T. N., Makale, J. O., Liljander, A., Urban, B. C., Bull, P. C., Szestak, T., Marsh, K. and Craig, A. G. (2011). Specific receptor usage in Plasmodium falciparum cytoadherence is associated with disease outcome. PLoS One 6, e14741.CrossRefGoogle ScholarPubMed
Oguariri, R. M., Mattei, D., Tena-Tomas, C., Uhlemann, A. C., Kremsner, P. G. and Kun, J. F. (2003). Recombinant Duffy binding-like-alpha domains of Plasmodium falciparum erythrocyte membrane protein 1 elicit antibodies in rats that recognise conserved epitopes. Parasitology Research 90, 467472.CrossRefGoogle ScholarPubMed
Otto, T. D., Rayner, J. C., Bohme, U., Pain, A., Spottiswoode, N., Sanders, M., Quail, M., Ollomo, B., Renaud, F., Thomas, A. W., Prugnolle, F., Conway, D. J., Newbold, C. and Berriman, M. (2014). Genome sequencing of chimpanzee malaria parasites reveals possible pathways of adaptation to human hosts. Nature Communications 5, 4754.CrossRefGoogle ScholarPubMed
Patarroyo, M. E., Alba, M. P., Curtidor, H., Vanegas, M., Almonacid, H. and Patarroyo, M. A. (2014). Using the PfEMP1 head structure binding motif to deal a blow at severe malaria. PLoS ONE 9, e88420.CrossRefGoogle Scholar
Rask, T. S., Hansen, D. A., Theander, T. G., Gorm Pedersen, A. and Lavstsen, T. (2010). Plasmodium falciparum erythrocyte membrane protein 1 diversity in seven genomes – divide and conquer. PLoS Computational Biology 6, pii e1000933.CrossRefGoogle ScholarPubMed
Rathore, U., Kesavardhana, S., Mallajosyula, V. V. and Varadarajan, R. (2014). Immunogen design for HIV-1 and influenza. Biochimica et Biophysica Acta 1844, 18911906.CrossRefGoogle ScholarPubMed
Reeder, J. C., Rogerson, S. J., Al-Yaman, F., Anders, R. F., Coppel, R. L., Novakovic, S., Alpers, M. P. and Brown, G. V. (1994). Diversity of agglutinating phenotype, cytoadherence, and rosette-forming characteristics of Plasmodium falciparum isolates from Papua New Guinean children. American Journal of Tropical Medicine and Hygiene 51, 4555.CrossRefGoogle ScholarPubMed
Roberts, D. J., Craig, A. G., Berendt, A. R., Pinches, R., Nash, G., Marsh, K. and Newbold, C. I. (1992). Rapid switching to multiple antigenic and adhesive phenotypes in malaria. Nature 357, 689692.CrossRefGoogle ScholarPubMed
Robinson, B. A., Welch, T. L. and Smith, J. D. (2003). Widespread functional specialization of Plasmodium falciparum erythrocyte membrane protein 1 family members to bind CD36 analysed across a parasite genome. Molecular Microbiology 47, 12651278.CrossRefGoogle ScholarPubMed
Roca-Feltrer, A., Carneiro, I., Smith, L., Schellenberg, J. R., Greenwood, B. and Schellenberg, D. (2010). The age patterns of severe malaria syndromes in sub-Saharan Africa across a range of transmission intensities and seasonality settings. Malaria Journal 9, 282.CrossRefGoogle ScholarPubMed
Rottmann, M., Lavstsen, T., Mugasa, J. P., Kaestli, M., Jensen, A. T., Muller, D., Theander, T. and Beck, H. P. (2006). Differential expression of var gene groups is associated with morbidity caused by Plasmodium falciparum infection in Tanzanian children. Infection and Immunity 74, 39043911.CrossRefGoogle ScholarPubMed
Rovira-Vallbona, E., Monteiro, I., Bardaji, A., Serra-Casas, E., Neafsey, D. E., Quelhas, D., Valim, C., Alonso, P., Dobano, C., Ordi, J., Menendez, C. and Mayor, A. (2013). VAR2CSA signatures of high Plasmodium falciparum parasitemia in the placenta. PLoS ONE 8, e69753.CrossRefGoogle ScholarPubMed
Rowe, A., Obeiro, J., Newbold, C. I. and Marsh, K. (1995). Plasmodium falciparum rosetting is associated with malaria severity in Kenya. Infection and Immunity 63, 23232326.CrossRefGoogle ScholarPubMed
Rowe, J. A., Moulds, J. M., Newbold, C. I. and Miller, L. H. (1997). P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1. Nature 388, 292295.CrossRefGoogle ScholarPubMed
Rowe, J. A., Claessens, A., Corrigan, R. A. and Arman, M. (2009). Adhesion of Plasmodium falciparum-infected erythrocytes to human cells: molecular mechanisms and therapeutic implications. Expert Reviews in Molecular Medicine 11, e16.CrossRefGoogle ScholarPubMed
Salanti, A., Staalsoe, T., Lavstsen, T., Jensen, A. T., Sowa, M. P., Arnot, D. E., Hviid, L. and Theander, T. G. (2003). Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Molecular Microbiology 49, 179191.CrossRefGoogle ScholarPubMed
Saul, A. (1999). The role of variant surface antigens on malaria-infected red blood cells. Parasitology Today 15, 455457.CrossRefGoogle ScholarPubMed
Severins, M., Klinkenberg, D. and Heesterbeek, H. (2012). How selection forces dictate the variant surface antigens used by malaria parasites. Journal of the Royal Society Interface 9, 246260.CrossRefGoogle ScholarPubMed
Smith, J. D. (2014). The role of PfEMP1 adhesion domain classification in Plasmodium falciparum pathogenesis research. Molecular and Biochemical Parasitology 195, 8287.CrossRefGoogle ScholarPubMed
Smith, J. D., Chitnis, C. E., Craig, A. G., Roberts, D. J., Hudson-Taylor, D. E., Peterson, D. S., Pinches, R., Newbold, C. I. and Miller, L. H. (1995). Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 82, 101110.CrossRefGoogle ScholarPubMed
Smith, J. D., Kyes, S., Craig, A. G., Fagan, T., Hudson-Taylor, D., Miller, L. H., Baruch, D. I. and Newbold, C. I. (1998). Analysis of adhesive domains from the A4VAR Plasmodium falciparum erythrocyte membrane protein-1 identifies a CD36 binding domain. Molecular and Biochemical Parasitology 97, 133148.CrossRefGoogle ScholarPubMed
Smith, J. D., Craig, A. G., Kriek, N., Hudson-Taylor, D., Kyes, S., Fagan, T., Pinches, R., Baruch, D. I., Newbold, C. I. and Miller, L. H. (2000). Identification of a Plasmodium falciparum intercellular adhesion molecule-1 binding domain: a parasite adhesion trait implicated in cerebral malaria. Proceedings of the National Academy of Sciences of the United States of America 97, 17661771.CrossRefGoogle ScholarPubMed
Stevenson, L., Huda, P., Jeppesen, A., Laursen, E., Rowe, J. A., Craig, A., Streicher, W., Barfod, L. and Hviid, L. (2014). Investigating the function of F -specific binding of IgM to Plasmodium falciparum erythrocyte membrane protein 1 mediating erythrocyte rosetting. Cellular Microbiology 17, 819831.CrossRefGoogle Scholar
Su, X., Heatwole, V. M., Wertheimer, S. P., Guinet, F., Herrfeldt, J. A., Peterson, D. S., Ravetch, J. A. and Wellems, T. E. (1995). The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes. Cell 82, 89100.CrossRefGoogle ScholarPubMed
Taylor, T. E., Fu, W. J., Carr, R. A., Whitten, R. O., Mueller, J. S., Fosiko, N. G., Lewallen, S., Liomba, N. G. and Molyneux, M. E. (2004). Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nature Medicine 10, 143145.CrossRefGoogle ScholarPubMed
Tebo, A. E., Kremsner, P. G., Piper, K. P. and Luty, A. J. (2002). Low antibody responses to variant surface antigens of Plasmodium falciparum are associated with severe malaria and increased susceptibility to malaria attacks in Gabonese children. American Journal of Tropical Medicine and Hygiene 67, 597603.CrossRefGoogle ScholarPubMed
Tembo, D. L., Nyoni, B., Murikoli, R. V., Mukaka, M., Milner, D. A., Berriman, M., Rogerson, S. J., Taylor, T. E., Molyneux, M. E., Mandala, W. L., Craig, A. G. and Montgomery, J. (2014). Differential PfEMP1 expression is associated with cerebral malaria pathology. PLoS Pathogens 10, e1004537.CrossRefGoogle ScholarPubMed
Turner, L., Lavstsen, T., Berger, S. S., Wang, C. W., Petersen, J. E., Avril, M., Brazier, A. J., Freeth, J., Jespersen, J. S., Nielsen, M. A., Magistrado, P., Lusingu, J., Smith, J. D., Higgins, M. K. and Theander, T. G. (2013). Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature 498, 502505.CrossRefGoogle ScholarPubMed
van Noort, S. P., Nunes, M. C., Weedall, G. D., Hviid, L. and Gomes, M. G. (2010). Immune selection and within-host competition can structure the repertoire of variant surface antigens in Plasmodium falciparum – a mathematical model. PLoS ONE 5, e9778.CrossRefGoogle ScholarPubMed
Vigan-Womas, I., Guillotte, M., Juillerat, A., Vallieres, C., Lewit-Bentley, A., Tall, A., Baril, L., Bentley, G. A. and Mercereau-Puijalon, O. (2011). Allelic diversity of the Plasmodium falciparum erythrocyte membrane protein 1 entails variant-specific red cell surface epitopes. PLoS ONE 6, e16544.CrossRefGoogle ScholarPubMed
Vigan-Womas, I., Guillotte, M., Juillerat, A., Hessel, A., Raynal, B., England, P., Cohen, J. H., Bertrand, O., Peyrard, T., Bentley, G. A., Lewit-Bentley, A. and Mercereau-Puijalon, O. (2012). Structural basis for the ABO blood-group dependence of Plasmodium falciparum rosetting. PLoS Pathogens 8, e1002781.CrossRefGoogle ScholarPubMed
Wang, C. W., Hermsen, C. C., Sauerwein, R. W., Arnot, D. E., Theander, T. G. and Lavstsen, T. (2009). The Plasmodium falciparum var gene transcription strategy at the onset of blood stage infection in a human volunteer. Parasitology International 58, 478480.CrossRefGoogle Scholar
Warimwe, G. M., Keane, T. M., Fegan, G., Musyoki, J. N., Newton, C. R., Pain, A., Berriman, M., Marsh, K. and Bull, P. C. (2009). Plasmodium falciparum var gene expression is modified by host immunity. Proceedings of the National Academy of Sciences of the United States of America 106, 2180121806.CrossRefGoogle ScholarPubMed
Warimwe, G. M., Fegan, G., Musyoki, J. N., Newton, C. R., Opiyo, M., Githinji, G., Andisi, C., Menza, F., Kitsao, B., Marsh, K. and Bull, P. C. (2012). Prognostic indicators of life-threatening malaria are associated with distinct parasite variant antigen profiles. Science Translational Medicine 4, 129ra45.CrossRefGoogle ScholarPubMed
Warimwe, G. M., Fegan, G., Musyoki, J. N., Newton, C. R., Opiyo, M., Githinji, G., Andisi, C., Menza, F., Kitsao, B., Marsh, K. and Bull, P. C. (2012). Prognostic indicators of life-threatening malaria are associated with distinct parasite variant antigen profiles. Science Translational Medicine 4, 129–145.CrossRefGoogle ScholarPubMed
Warimwe, G. M., Recker, M., Kiragu, E. W., Buckee, C. O., Wambua, J., Musyoki, J. N., Marsh, K. and Bull, P. C. (2013). Plasmodium falciparum var gene expression homogeneity as a marker of the host-parasite relationship under different levels of naturally acquired immunity to malaria. PLoS ONE 8, e70467.CrossRefGoogle ScholarPubMed
Whitrow, M. (1990). Wagner-Jauregg and fever therapy. Medical History 34, 294310.CrossRefGoogle ScholarPubMed
Wilson, D. B., Garnham, P. C. and Swellengrebel, N. H. (1950). A review of hyperendemic malaria. Tropical Diseases Bulletin 47, 677698.Google ScholarPubMed
Yone, C. L., Kremsner, P. G. and Luty, A. J. (2005). Immunoglobulin G isotype responses to erythrocyte surface-expressed variant antigens of Plasmodium falciparum predict protection from malaria in African children. Infection and Immunity 73, 22812287.CrossRefGoogle ScholarPubMed
Zilversmit, M. M., Chase, E. K., Chen, D. S., Awadalla, P., Day, K. P. and McVean, G. (2013). Hypervariable antigen genes in malaria have ancient roots. BMC Evolutionary Biology 13, 110.CrossRefGoogle ScholarPubMed
Figure 0

Fig. 1. Hypothetical trade-offs between function and antigenic novelty. This figure shows an immunological version of the principle of functional constraint focusing on efficiency of biological functions associated with the host–parasite interaction (y-axis) and the hypothetical antigenic space within which those functions exist (x-axis). Optimal function can only be performed by a narrow range of molecular structures which translates, in the simplest case, to a small antigenic space. Key to virulence is not simply the function itself, but the ability of molecules or systems of molecules to uncouple immunogenicity from function to expand the antigenic space available. Hypothetical lines are drawn to suggest trade-offs between function and antigenic space in for: (i) Measles haemagglutinin (Frank and Bush, 2007), (ii) var2CSA, (iii) group A and DC8 PfEMP1 (Buckee and Recker, 2012), (iv) group B and C PfEMP1, (vi) HIV gp120 (de Boer and Boerlijst, 1994). Following from this hypothetical trade-off, parasites with high levels of recognition by antibodies commonly carried by children have been proposed to express PfEMP1 variants with strong cytoadhesive function and exist within a small restricted immunological space. Such hypothetical variants have been called: agglutination frequency high (AFH (Bull et al.2000) VSA with a high frequency of recognition [VSAFoRH (Bull et al.2005b)], and VSA associated with severe malaria [VSASM (Nielsen et al.2002; Jensen et al.2004)]. Their position within the graph is indicated with a box

Figure 1

Fig. 2. The structures of some notable PfEMP1 variants. Duffy-binding domains (DBL) are shown as rectangles and cysteine-rich interdomain regions (CIDR) and the CIDR-like domain of var2CSA are shown as ovals, N-terminal segment and acidic terminal segment (ATS) sequences are shown as hatched and stippled squares, respectively. ID2a and ID2b are interdomain regions within var2CSA that from part of the DBL2X CSA-binding domain (Clausen et al.2012). Cytoadhesion phenotypes associated with specific domains are shown as colours. Recombinant proteins derived from these PfEMP1 are shown as black horizontal lines under the region of the molecules from which they were derived a, b, c, d, e, f. Domain cassettes are shown as horizontal dashed lines: a, the Id1-DBL2X region can stimulate antibodies in mice that inhibit CSA binding (Bordbar et al.2012); b, The r179 region of CD36-binding CIDR from the Malayan Camp line used by Baruch et al. (1997) to induce homologous protection in Aotus monkeys; c, the region of the IgM binding, rosette mediating TM284var1 used by Ghumra et al. (2012) to induce cross-reactive, opsonizing antibodies in rabbits; IT4var60 was found to be the rosette mediating var in the well-studied cell line FCR3S1·2 (Albrecht et al.2011); d,e, constructs from non-IgM-binding, rosette-mediating PfEMP1 found to induce non-cross-reactive, rosette-inhibiting antibodies (Vigan-Womas et al.2011); (Ghumra et al.2012); The R29 line was recently found to simultaneously form rosettes and bind to human brain endothelial cells (Adams et al.2014); f, naturally acquired antibodies to the DBLβ4 domain of pf11_0008 were associated with protection from future malaria in a longitudinal study (Magistrado et al.2007). A PECAM1-binding domain cassette (DC5) was subsequently identified within this gene (Berger et al.2013). Also shown are DCs, DC4 found to bind ICAM1 (Bengtsson et al.2013), identified within var4 previously found to be dominantly expressed in parasites selected for binding to antibodies from semi-immune children (Jensen et al.2004). Note the additional presence of a CIDRα1.6 within var4, shown to bind to EPCR by Lau et al. (2015) but not by Turner et al. (2013). IT4var6 and IT4var19 were two genes selected for binding to cells lines derived from human brain endothelial cells (Avril et al.2012; Claessens et al.2012), within which the DC8 and the EPCR-binding CIDRa1·1 domain was identified (Turner et al.2013).

Figure 2

Table 1. Immunological studies on PfEMP1 domains

Figure 3

Table 2. A summary of PfEMP1 expression studies in clinical parasite isolates